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Abstract 
Prokineticin-1 (PK-1) and prokineticin-2 (PK-2) are two closely related cysteine-rich 
peptides which both bind to the prokineticin-1 and prokineticin-2 receptors (PKR-1 and 
PKR-2). The prokineticins were originally named due to their ability to stimulate 
gastrointestinal motility. Since that time, these peptides have been found to play a role 
in other biological processes including reproduction and nociception. Prokineticin-2 is 
known to be expressed in regions of the central nervous system involved in food intake. 
Consistent with this, work from our own department has shown that administration of 
prokineticin-2 to rodents reduces food intake both in lean and obese rodents.  
Prokineticin-2 is predominantly expressed within the central nervous system, whereas 
prokineticin-1 is heavily expressed in the gut. My pilot data showed that prokineticin 1 
reduces food intake in rodents. I therefore hypothesised that prokineticin 1 may be a 
novel gut hormone. In this thesis, I investigate the role of prokineticin-1 on appetite in 
rodents and also compare the effects of prokineticin-1 with prokineticin-2. I also 
measured the changes in plasma levels of prokineticin in humans during feeding to 
establish the potential physiological relevance of prokineticin-1 as an anorectic gut 
hormone.  
Prokineticin-1 is also a potent angiogenic mitogen on endocrine vascular epithelium and 
hence it is also known as ‘Endocrine Gland-Vascular Endothelial Factor’. Placental 
angiogenesis plays an important role in placental function and risk of pregnancy 
complications such as miscarriage. I therefore hypothesised that prokineticin-1 is a 
biomarker of pregnancy complications in humans. In this thesis, I have measured 
circulating levels of prokineticin-1 found in pregnancy and correlated these with the 
occurrence of pregnancy complications. I have also compared the utility of prokineticin 
1 with other potential novel markers of pregnancy complications. Together this body of 
work investigates the potential physiological roles of prokineticin-1. 
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The obesity epidemic 
 
According to the CDC (Centers for Disease Control and Prevention), 35.7% of adults in 
the USA are obese, as defined by a BMI (Body Mass Index) greater than 30 kg/m
2
 
(Ogden et al., 2010). The WHO define a normal body weight as a BMI of 20-25 kg/m
2
, 
25-30 kg/m
2
 as overweight, over 30 kg/m
2
 as ‘obese’, and a BMI of greater than 35 
kg/m
2
 morbid obesity. A recent survey published in March 2014 by the Gallup-
Healthways Well-Being Index suggests that the prevalence of obesity in the USA is 
increasing year upon year. Importantly, the survey also reported that people living in the 
10 states with the highest levels of obesity are more likely to carry a diagnosis of a 
chronic diseases such as high blood pressure, high cholesterol, depression, diabetes, 
cancer, and heart attacks, than are those living in the 10 states with the lowest obesity 
rates in data from 2009-2010.  
In Britain the incidence and prevalence of obesity is rising rapidly; in 1980 eight 
percent of women and six percent of men were classified as obese, which rose to over 
half of women and two thirds of men being classified as overweight or obese in 2001. 
Furthermore, the prevalence of childhood overweight and obesity in the U.K. has 
increased sharply over the last two decades affecting almost fourteen percent of boys 
and seventeen percent of girls aged two to fifteen years old. A prospective 
epidemiologic study of more than one million individuals has established that obesity is 
an independent risk factor for increased mortality and in addition, overweight and 
obesity cause significant morbidity including type II diabetes mellitus, certain cancers, 
coronary heart disease, hypertension, sleep apnoea, and psychological morbidity and 
societal stigmatisation (Calle et al. 1999; National audit office report; 2001). It has been 
estimated that the cost to the National Health Service (NHS) of treating obesity and its 
associated sequlae is 3.7 billion pounds per year which equates to just under three 
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percent of the total annual NHS budget. Obesity is a multifactorial condition in which 
genetic, environmental, psychological and socio-economic conditions influence food 
intake and body weight (Bray et al. 1992). However apetite regulation is the safest and 
likely to be the most effective therapeutic target for control of obesity, as therapies 
directed towards energy expenditure may carry a greater risk of adverse events. Apetite 
is tightly regulated by a complex interaction of neuronal and endocrine pathways many 
of which converge within the hypothalamus. The disruption of these hypothalamic 
pathways can result in changes in feeding behaviour and body weight and these findings 
have provided significant insights into the pathophysiology of obesity. Following the 
recent withdrawal of two anti-obesity drugs, there now exists only one agent (Orlistat) 
licensed for the treatment of obesity in the U.K. The patient drop out rate at one year for 
this sole remaining anti-obesity therapy is 70% which highlights the imperative to better 
understand appetite pathways in order to develop novel therapies for the treatment of 
obesity. The hypothalamic mechanisms controlling appetite are complex and plentiful; 
therefore a great deal of research is required in order to fully appreciate all of the 
different mechanisms and their interactions, such that new therapeutics for treating 
obesity can be developed.  
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The Hypothalamus 
The hypothalamus is a midline structure situated at the base of the brain with 
symmetrical right and left halves traversing each lateral wall of the third ventricle. The 
hypothalamus contains populations of neurones organised into discrete nuclear 
aggregations with inter and intra-nuclear connections (see Figure 1).  
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Figure 1: Diagrammatic representation of a sagittal section through a rodent 
brain showing the hypothalamic nuclei involved in the regulation of food intake.   
 
ARC, Arcuate nucleus; PVN, paraventricular nucleus; DMH, dorsomedial 
hypothalamus; VMH, ventromedial hypothalamus; LH, lateral hypothalamus. 
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The importance of the hypothalamus in body weight regulation came to the fore in the 
middle of the last century when it was reported that the lesioning of discrete 
hypothalamic nuclei could induce hyperphagia and obesity or aphagia and weight loss 
depending on the targeted nucleus (Hetherington et al. 1940). Since this time numerous 
studies have not only confirmed the importance of these hypothalamic nuclei in the 
regulation of body weight, but have also delineated many of the hypothalamic signals 
and pathways which control energy homeostasis (see Table 1). I shall briefly introduce 
the most prominent hypothalamic nuclei in turn and their role in appetite control, 
namely:  
i) The arcuate nucleus (ARC) 
ii) The paraventricular nucleus (PVN) 
iii) The lateral hypothalamus (LH) 
iv) The ventromedial nucleus (VMN) 
v) The dorsomedial nucleus 
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The Arcuate Nucleus (ARC)  
 
The arcuate nucleus (ARC) is located near the median eminence, where the blood brain 
barrier is incomplete. This renders the ARC susceptible to the effects of circulating 
factors, which signal information about nutritional status and the metabolic milieu. One 
such factor is the anorectic peptide hormone leptin, which is synthesised and secreted 
by adipocytes signalling information about energy stores and nutritional status, 
circulating at levels proportional to fat mass (Zhang et al. 1994).  
One population of ARC neurones co-expresses the orexigenic peptides neuropeptide Y 
(NPY) and agouti-related protein (AgRP), whilst a second subpopulation expresses the 
anorectic peptides alpha-melanocyte-stimulating hormone (α-MSH) derived from pro-
opiomelanocortin (POMC) and cocaine-and amphetamine-regulated transcript (CART). 
Both NPY/AgRP and POMC/CART neurones express the leptin receptor and the 
synthesis and release of these peptides is regulated by the level of circulating leptin. 
NPY is a potent orexigenic neuropeptide. The intracerebroventricular (ICV) injection of 
NPY into the third ventricle of rats results in a marked increase in food intake and NPY 
administration over a sustained period leads to weight gain (Vettor et al. 1994). When 
serum leptin levels are high indicating adequate energy storage in adipose tissue the 
synthesis and release of NPY is inhibited. Conversely when circulating leptin levels fall, 
NPY expression increases.  
The NPY expressing neurones of the ARC also express the orexigenic peptide AgRP, 
which shows a similar expression pattern in response to the level of circulating leptin as 
that of NPY. The agouti viable yellow mouse (Avy) which over expresses agouti 
protein is hyperphagic and obese. Furthermore, ICV administration of AgRP to rats 
increases food intake (Klebig et al. 1995; Rossi et al. 1998). Both AgRP and the ARC 
anorectic peptide α-MSH act upon the melanocortin 4 receptor (MC4R). 
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Physiologically, α-MSH mediates a basal tonic inhibition of food intake by agonist 
action at MC4R, whilst AgRP acts as an antagonist at the MC4R and stimulates food 
intake (Ollmann et al. 1997).  
The importance of the melanocortin system in the regulation of body weight in humans 
can be seen in the early onset obesity of children with mutations of MC4R, which may 
account for up to six percent of cases of morbid paediatric obesity (Yeo et al. 1998). 
Furthermore individuals with homozygous mutations of the POMC gene are obese and 
heterozygotes also have an increased prevalence of overweight and obesity (Krude et al. 
1998).  
The POMC neurones of the ARC also express the neuropeptide cocaine- and 
amphetamine regulated transcript (CART). CART has been shown to have both an 
anorectic and orexigenic effect depending on the site of action. The expression of 
CART mRNA in the ARC is reduced in food deprived animals, but can be increased by 
the administration of leptin. The ICV administration of CART reduces food intake 
which may be mediated in the hindbrain since plugging the aqueduct between the third 
and fourth ventricle prevents this anorectic effect (Kristensen et al. 1998). The 
orexigenic effect of CART may be mediated in the hypothalamus since the direct 
injection of CART into the ARC or the ventromedial nucleus stimulates feeding and the 
transgene mediated over expression of CART in the ARC leads to a significant increase 
in food intake (Kong et al. 2003).  
 
 
 
 25 
The Paraventricular nucleus (PVN) 
 
The paraventricular nucleus (PVN) is composed of a group of heterogeneous neurones 
situated on either side of the top of the third cerebral ventricle. Both NPY and 
melanocortin neurones of the ARC project to the PVN where MC4R and receptors for 
NPY are expressed. The direct injection of NPY and AgRP in to the PVN induces 
hyperphagia whilst the intra-PVN administration of an MSH analogue inhibits feeding 
(Kim et al. 2000). The leptin receptor is not highly expressed in the PVN and it is likely 
that the effect of leptin on PVN outflow is via projections from the leptin responsive 
neurones of other hypothalamic nuclei such as the ARC and the ventromedial nucleus. 
Therefore, the PVN may act as a final common pathway of the neuronal, autonomic and 
endocrine response to circulating leptin with projections to numerous sites outside the 
hypothalamus including higher centres known to modulate motivational behaviours, the 
pituitary gland and the sympathetic nervous system. 
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The Lateral Hypothalamus (LH) 
 
The lateral hypothalamus (LH) is a nucleus of the lateral zone of the hypothalamus. To 
date, two key groups of LH peptides, the orexins and melanin concentrating hormone 
(MCH) have been identified as having a marked orexigenic effect. Levels of orexin pre-
pro mRNA increase during fasting and the central administration of orexin stimulates 
food intake (Sakurai et al. 1998). Whilst the orexins were originally named for their 
stimulatory effect on food intake from the Greek ‘orexis’ meaning appetite, subsequent 
studies have demonstrated that the orexins play a significant role in behavioural arousal 
and in human narcolepsy, a condition of sudden irresistible day time somnolence has 
been shown to be associated with a deficiency of orexin or its receptor (Lin et al. 1999). 
Like the orexins, MCH mRNA expression in the LH also increases during starvation 
and returns to baseline after re-feeding (Qu et al. 1996). Furthermore, the injection of 
MCH into the LH results in an increase in food intake in rats whilst MCH knock out 
mice are hypophagic and have a lower body weight than wild type controls (Shimada et 
al. 1998). Within the hypothalamus the MCH receptor is expressed in the ARC and the 
ventromedial nucleus and following lesioning of the ventromedial nucleus in rats there 
is a marked increase in MCH expression in the LH, which may partly explain the 
hyperphagia of ventromedial nucleus lesioned animals.  
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The Ventromedial Nucleus (VMN) 
 
The ventromedial nucleus (VMN) of the hypothalamus is a bilateral group of 
encapsulated neuronal cell bodies and their dendritic branches that sits adjacent to the 
third ventricle above the ARC and below the dorsomedial nucleus (DMN).  
The importance of the VMN in the regulation of food intake was first demonstrated in 
the middle of the last century following experimental lesioning of the VMN in rats 
which resulted in hyperphagia and obesity (Hetherington et al. 1940). Soon after, it was 
reported that lesions of the LH resulted in aphagia and weight loss. The suggestion that 
the LH was a ‘feeding centre’ and the VMN a ‘satiety centre’ led to the ‘dual-centre’ 
hypothesis for motivated behaviour, which although now considered overly simplistic, 
nevertheless provided a framework for early studies investigating the hypothalamic 
regulation of food intake. 
The transcription factor steroidogenic factor-1 (SF-1) is an orphan member of the 
nuclear hormone receptor family and is expressed by VMN neurones which also 
express the leptin receptor. SF-1 knockout mice develop late onset obesity 
predominantly due to a reduction in locomotor activity (Majdic et al. 2002). 
Furthermore the targeted deletion of the leptin receptor from these neurones results in 
obesity which is not due to hyperphagia but attributable to reduced energy expenditure 
and impaired diet induced thermogenesis (Dhillon et al. 2006). The obesity of these 
mice with targeted VMN deletion of the leptin receptor is less marked compared to that 
of global receptor null mice but is augmented by the additional deletion of the leptin 
receptor on ARC POMC neurones (Dhillon et al. 2006).  
Brain derived neurotrophic factor (BDNF) is a mediator of brain development and 
plasticity and also has a well defined role as an anorectic neuropeptide (Xu et al. 2003). 
Infusion of BDNF into the lateral ventricle of rats results in a dose dependent reduction 
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in food intake and body weight. Within the hypothalamus, BDNF and its receptor are 
most abundantly expressed in the VMN where BDNF expression is co-localised with 
SF-1 expressing neurones. BDNF expression in the VMN but not in other brain regions 
is regulated by nutritional status with food deprivation resulting in a 60% reduction in 
BDNF mRNA in the VMN (Xu et al. 2003). When BDNF is selectively deleted in the 
VMN and DMN the mutant animals are hyperphagic and obese with normal energy 
expenditure (Xu et al. 2003). The importance of BDNF signalling in the regulation of 
human body weight is suggested by the phenotype of severe hyperphagic obesity in 
subjects with mutations in the gene for BDNF or its receptor (Gray et al. 2006, Yeo et 
al. 2004).  
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The Dorsomedial Nucleus (DMN)  
 
The dorsomedial nucleus (DMN) lies above the VMN in the mediobasal hypothalamus. 
The DMN receives afferent input from the VMN and LH and efferent fibres project to 
the PVN. The leptin receptor is expressed by DMN neurones which highly express the 
orexigenic peptide NPY. The tissue specific over expression of NPY in the DMN of rats 
using adeno-associated virus (AAV) results in an increase in food intake and body 
weight whilst knockdown of NPY in the DMN normalises the food intake of Otsuka 
Long-Evans Tokushima Fatty rats, a strain which is hyperphagic and obese due to the 
congenital absence of the receptor for the anorectic gut peptide cholecystokinin CCK 
(Yang et al. 2009).  
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Circulating Factors which act within the hypothalamus to regulate food intake and 
body weight 
 
 
In addition to leptin, several other circulating factors, produced in the periphery, act 
within the hypothalamus to regulate food intake and body weight. These signals include 
hormones produced by the gastro-intestinal tract and the thyroid hormone, tri-
iodothyronine (T3).  
The orexigenic peptide ghrelin is produced by the stomach and circulating levels rise 
during fasting and fall following food intake. The administration of ghrelin to rats 
results in the stimulation of feeding which is partly mediated by activation of 
NPY/AgRP neurones of the ARC (Nakazato et al. 2001). Obese subjects have been 
found to have reduced ghrelin suppression after a meal compared with normal weight 
controls and ghrelin levels have been found to increase after diet-induced weight loss 
which could jeopardise the maintenance of weight reduction (Cummings et al. 2002).  
Peptide YY (PYY) is a peptide hormone released from by the colon following food 
ingestion. It exerts an anorectic effect in the ARC through the inhibition of orexigenic 
NPY neurones and disinhibition of anorectic POMC neurones (Batterham et al. 2002). 
Obese humans have been found to have a reduced post-prandial rise in plasma PYY 
compared with lean controls and this is associated with an attenuated satiety response 
(le Roux et al. 2006). Furthermore, circulating PYY levels rise following gastric bypass 
surgery which may partly explain the reduced appetite reported by some subjects 
following this procedure.  
The anorectic gut peptide glucagon-like peptide-1 (GLP-1) is released following food 
intake and levels of expression fall with fasting. The direct injection of GLP-1 into the 
PVN reduces food intake in rats and evidence for the physiological importance of GLP-
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1 is suggested by the orexigenic effect of the central administration of the specific a 
GLP-1 receptor antagonist to satiated rats which when given for ten days significantly 
increases body weight (Turton et al. 2006). Obese humans have been found to have an 
attenuated postprandial release of GLP-1 and reduced circulating levels of the hormone 
which increases with weight loss.  
Oxyntomodulin (OXM) is co-secreted with GLP-1 and PYY following a meal. OXM 
promotes satiety in both rodents and humans and this effect may partly be through the 
augmentation of ARC α-MSH signalling (Dakin et al. 2006). In addition, part of OXM’s 
suppressive effect on food intake may be due to a reduction in plasma ghrelin. 
Circulating OXM levels are raised after gastric bypass surgery which may contribute to 
the weight reducing effect of the procedure.  
The importance of thyroid hormones in the regulation of energy homeostasis is attested 
by the hyperphagia and weight loss seen in patients with hyperthyroidism and the 
reduced metabolic rate and weight gain of hypothyroidism. During fasting T3 is 
produced within the hypothalamus from circulating thyroxine (T4) and in rodents the 
administration of T3 directly into the VMN stimulates food intake although the 
mechanism by which this occurs is not known (Kong et al. 2004; Diano et al. 1998). 
Appetite regulation is thought to be coordinated at the ARC, whereby peripheral signals 
such as leptin act to modulate the release of orexigenic and anorectic neuropeptides via 
the MC4R and control appetite and thus body weight. This model allows for the 
communication of peripheral signals of energy stores to the hypothalamus to regulate 
energy stores.  
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Table 1: Neuropeptides and hormones implicated in regulation of appetite. 
 
Orexigenic Peptides Anorectic Peptides 
 
Neuropeptide Y (NPY) 
Agouti related peptide (AgRP) 
Melanin concentrating hormone (MCH) 
Galanin 
Orexin-A and –B 
-endorphin 
Neuromedin U / S 
 
Circulating Factors: 
Ghrelin 
 
 
α-melanocyte stimulating hormone (α-MSH) 
Corticotrophin releasing hormone (CRH) 
Thyrotrophin releasing hormone (TRH) 
Cocaine-and amphetamine-related transcript 
(CART) 
Glucagon-like peptide-1 (GLP-1) 
Oxyntomodulin (Oxm) 
Bombesin 
Somatostatin 
Amylin 
 
Circulating Factors: 
Insulin 
Leptin 
Glucagon 
Cholecystokinin (CCK) 
Pancreatic polypeptide (PP) 
Peptide YY (PYY) 
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Prokineticins- a potential novel regulator of appetite 
 
A recently discovered family of peptides called the prokineticins may be involved in a 
variety of physiological functions including appetite regulation and reproduction. 
 
Prokineticins 
 
In 2000, Lie et al. isolated two human cDNAs and their encoded proteins, which were 
named ‘Prokineticins’ (PKs) due to their ability to stimulate gastrointestinal (GI) 
smooth muscle in guinea pig ileum (Li et al., 2001).  The two forms of prokineticin 
(PK), prokineticin-1 (PK-1) and prokineticin-2 (PK-2), share approximately 44% amino 
acid homology (Li et al. 2001; LeCouter et al. 2001).  Prokineticin 1 (PK-1) and 
prokineticin 2 (PK-2) were first identified as the mammalian homologues of the 
amphibian peptide mamba intestinal toxin (MIT-1; a non-toxic constituent in the venom 
of the black mamba snake Dendroaspis polylepis) and Bv8 (Bombina variegate 
molecular mass-8 kDa: found in the skin secretion of the toad Bombina variegate) 
respectively. Prokineticin-1 (PK-1) is also known as endocrine gland vascular 
endothelial growth factor (EGVEGF) (Ngan et al. 2008).  
More recently, molecular cloning analysis has identified a longer form peptide of PK-2, 
PK-2L. PK-2L is an alternatively spliced product of the PK-2, which contains 21 
additional amino acids. Proteolytic cleavage of PK-2L generates the smaller active form 
of PK-2 protein termed PK-2β (Chen et al., 2005). 
The genes encoding PK-1 and PK-2 are located on human chromosome 1p21 and 
3p21.1, respectively. The six amino acid sequence at the N-terminal domain of the PKs 
(AVITGA) are highly conserved between mammalian and non-mammalian species.  
The C-terminal domain contains 10 cysteine residues which form five pairs of 
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disulphide bonds (see Figure 2 and 3) and fold the molecule into a globular form (Li et 
al. 2001; Mollay et al. 1999; Boisouvier et al. 1998).   
These prokineticins have been found to play a role in a number of biological processes 
including appetite and reproduction. Prokineticin 2 has been shown to be required for 
the formation of the olfactory bulb. Patients lacking prokineticin 2 are unable to secrete 
GnRH with resultant hypogonadotrophic hypogonadism. Data from our own department 
has shown that administration of prokineticin 2 to rodents reduces food intake both in 
lean and obese rodents.  
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Figure 2: The amino acid sequence of Prokineticin-2 (PK-2).   
Ten conserved cysteine residues are highlighted in colour and pairs of disulphide bonds 
are based on the sequence of mamba intestinal toxin 1 (MIT 1) (Wen et al., 2005). See 
Appendix 2 for amino acid codes.  
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Figure 3: Amino Acid Sequence of Prokineticin-1 and Prokineticin-2 
Amino acid sequences of prokineticin 1 (A), prokineticin 2 (B), Frog Bv8 (C), and 
partial sequence of MIT 1 (D). The ten conservative cysteine residues are marked (*). 
Signal peptides are underlined (Li et al. 2001). 
 
Human PK-1 sequence (86 αα) is :  
(N-terminal) AVITGACERDVQCGAGTCCAISLWLRGLRMCTPLGREGEECHP 
GSHKIPFFRKRKHHTCPCLPNLLCSRFPDGRYRCSMDLKNINF (C-terminal) 
 
and Human PK-2 (81 αα) sequence is :  
AVITGACDKDSQCGGGMCCAVSIWVKSIRICTPMGKLGDSCHPLTRKVPFFGRR
MHHTCPCLPGLACLRTSFNRFICLAQK 
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The PK’s are the ligands for two closely related cognate G-protein coupled receptors 
(GPCRs), termed prokineticin receptor-1 (PKR-1) and prokineticin receptor-2 (PKR-2) 
(Lin et al., 2002, Masuda et al., 2002). PKR-1 and PKR-2 are encoded by genes located 
on human chromosome region 2q14 and 20p13 respectively (Kaser et al., 2003). These 
receptors share 85% amino acid identity and differ mainly in their N-terminal sequences 
(Kaser et al., 2003). Receptors couple to Gq, Gi and Gs to mediate the intracellular 
calcium mobilisation, phosphorylation of p44/p42 mitogen-activated protein kinase, 
serine/threonine kinase Akt and cAMP accumulation, respectively (Chen et al., 2005). 
Receptor binding and functional assays have revealed that PK’s exhibit different 
affinities for the receptors and potencies in activating calcium mobilisation. PK-2 has 
greater affinity than PK1 (and PK2β) for both PK receptors 1 and 2 (Chen et al. 2005). 
PK2β has greater affinity for PKR-1 rather than PKR-2 (Chen et al. 2005).  The N-
terminal amino acid sequence (AVITGA) is essential for activation of PKR’s, since 
invertebrate homologues of PK’s which lack AVITGA do not activate mammalian 
PKR’s (Negri et al., 2007).  Furthermore, PK’s with mutant N-terminal domains fail to 
activate the PKR’s (Bullock et al., 2004). The C-terminal cysteine residues are equally 
important, since mutant PK’s with substitutions of cysteine residues from the C-
terminal also result in failure of activation of PKR’s (Bullock et al., 2004). PK-1 and 
PKR-1 are expressed predominantly in peripheral tissues, whereas expression of PK-2 
and PKR-2 is highest in the brain (Li et al., 2001, Masuda et al., 2002).  
 
The wide expression of PK’s within the central nervous system (CNS) and the periphery 
suggests that they may play a role in several biological functions.  The distribution and 
possible biological roles are summarised in Table 2.  
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Table 2: Distribution of expression of prokineticins and their receptors 
Expression of prokineticins (PKs) and prokineticin receptors (PKRs) throughout the 
body (adpated from Ngan et al. 2008). 
        
 
Tissues 
 
PK-1 
 
PK-2 
 
PK-R1 
 
PK-R2 
 
Reference 
 
Ovary 
 
Granulosa; 
corpus luteum 
 
Not detected Present Present 
LeCouter et al. (2001) 
Maldonado-Perez et al. (2007) 
Testis Leydig cells Spermatocytes 
 
Endothelial cells 
of testis 
interstitium 
 
Endothelial cells 
of testis 
interstitium 
Maldonado-Perez et al.(2007) 
Adrenal 
gland 
Glomerulosa 
cell; 
fasciculate cells 
 
 
Glomerulosa 
cell; 
fasciculate cells; 
endothelial cells 
 
Glomerulosa cell; 
fasciculate cells; 
endothelial cells 
Glomerulosa cell; 
fasciculate cells 
Keramidas et al. 2008) 
 
Placenta Present Present Present Not detected 
Chen et al. (2005) 
Maldonado-Perez et al. (2007) 
uterus 
 
Glandular 
epithelium; 
endothelial; 
stromal cells; 
smooth muscle 
cells 
 
Glandular 
epithelium; 
endothelial; 
stromal cells; 
smooth muscle 
cells 
 
Glandular 
epithelium; 
endothelial; 
stromal cells; 
smooth muscle 
cells 
 
Glandular 
epithelium; 
endothelial; 
stromal cells; 
smooth muscle 
cells 
Maldonado-Perez et al. (2007) 
Ngan et al. (2006) 
Brain Low expression 
Cerebral cortex; 
olfactory bulb; 
Purkinje cells 
 
Subventricular 
zone; 
rostal migratory 
stream; olfactory 
bulb; 
hippocampus 
 
Subventricular 
zone; 
rostal migratory 
stream; olfactory 
bulb; 
hippocampus 
Cheng et al. (2002) 
Ng et al. (2005) 
Intestinal 
tract 
 
Enteric plexus; 
mucosa of 
embryonic gut 
 
Enteric plexus 
 
Enteric plexus; 
enteric neural 
crest cells 
Enteric plexus of 
ileocecum 
 
Hoogerwerf (2006), 
Kaser et al. (2003), 
Ngan et al. (2007) 
Ngan et al. (2008) 
 
Heart 
 
 
Cardiovascular 
tissue; cardiac 
cell 
 
 
Cardiovascular 
tissue; 
cardiac cell 
 
 
Cardiovascular 
tissue; cardiac 
cell 
 
No detected 
 
 
Urayama et al. (2007) 
 
 
Bone 
marrow; 
peripheral 
blood 
B and T cells 
Hematopoietic 
stem cells; 
monocytes; 
neutrophils and 
dendritic cells 
Hematopoietic 
stem cells; 
mature blood 
cells including 
lymphocytes 
Hematopoietic 
stem cells; 
mature blood 
cells including 
lymphocytes 
LeCouter et al. (2004) 
Lin et al. (2002) 
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In rodents, PK-1 expression has been identified in the gastrointestinal tract, ovaries, 
testes, adrenals, the placenta and the nucleus tractus solitarius (NTS) (Cheng et al. 
2002; LeCouter et al. 2003; Melchiorri et al. 2001; Wechselberger et al. 1999).  
Interestingly, the expression of PK-1 is dynamic in the reproductive organs (ovary, 
uterus and placenta) and changes in response to changes in the hormonal milieux 
(oestrogen, progesterone, human chorionic gonadotropin (hCG) and hypoxia-inducible 
factor (HIF-1α)) across the menstrual cycle and during pregnancy (Maldonado-Perez et 
al., 2007; Ngan et al., 2006). 
Like PK-1, PK-2 mRNA has been reported in the small intestine and testes (Li et al., 
2002; Wechselberger et al., 1999), but PK-2 is mainly localised to the brain.  PK-2 in 
the brain is present in the olfactory bulb, regions of the cerebral cortex, medial pre-optic 
area (MPOA) of the hypothalamus, the ARC, suprachiasmatic nucleus (SCN), some 
thalamic nuclei, Purkinje cells of the cerebellum, sensory and motor nuclei of the brain 
stem and spinal cord.  PK-2 mRNA is rhythmically expressed in the SCN, according to 
the 24-h cycle of the circadian clock (Cheng et al., 2002). 
Both PKR’s are present in the testis and several regions of the brain.  In the mouse 
brain, PKR-2 mRNA is expressed in the lateral septal nucleus (LS), paraventricular, 
parataenial and paracentral thalamic nuclei (PVT / PT / PC), paraventricular nucleus 
(PVN), dorso medial hypothalamus (DMH), arcuate (ARC), suprachiasmatic nucleus 
(SCN), subfornical organ (SFO), lateral globus pallidus, amygdala, nucleus tractus 
solitarus (NTS) and area postrema (AP) (Cheng et al., 2002, Cheng et al., 2006).  PKR-
1 mRNA has limited distribution within the CNS, with only moderate expression in the 
olfactory regions, dentate gyrus, zona incerta and dorsal motor vagal nucleus (Cheng et 
al. 2006). 
PK-2 has been shown to be required for normal GnRH secretion and fertility. Mice 
lacking either PK-2 or the PKR-2 have a marked reduction in olfactory bulb size (Ng et 
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al. 2005; Matsumoto et al. 2006).  Furthermore, the absence of either PK-2 or PKR-2 in 
mice or humans results in hypogonadotrophic hypogonadism, and a failure of 
gonadotrophin releasing hormone (GnRH) neuronal migration (Cole et al. 2008; Dode 
et al. 2006; Pitteloud et al. 2007; Matsumoto et al. 2006).  PK-2 also plays a role in 
nociception, as absence of PK-2 in mice results in impaired perception of pain and 
administration of PK-2 to mice results in hyperalgesia (Hu et al., 2006). 
PK-2 is expressed at high levels in the SCN of the hypothalamus and is therefore 
believed to play an important role in the regulation of the circadian cycle.  Mice lacking 
PK-2 or PKR-2 show disrupted sleep-wake cycles, locomotor activity and 
thermogenesis (Li et al. 2006, Prosser et al. 2007).  The regulation of food intake is 
influenced by the circadian rhythms (Froy et al. 2007) and thus PK-2 signalling may 
influence food intake. Neurons from the SCN project to various hypothalamic regions 
important in the control of food intake that express PKR mRNA, including the ARC, 
PVN and the DMH (Negri et al. 2004; Cheng et al. 2002). Consistent with this, PK-2 
expression in the SCN is highest in the early light phase (when rats are satiated) and 
lowest at the beginning of the dark phase (natural feeding period) suggesting that PK-2 
may act to physiologically inhibit food intake (Negri et al. 2004).   
The frog homologue of the mammalian PK-2 (BV8) binds with high affinity to the 
PKR-2 and inhibits food intake following intracerebroventricular (ICV) or direct ARC 
injection in food-deprived rats (Negri et al. 2004).  The ARC receives neuronal inputs 
from the SCN, MPO and NTS, neurones all of which express PK-2 (Negri et al. 2004). 
Interestingly, PK-2 has been shown to directly activate neurones in the PVN using 
whole-cell patch-clamp techniques (Yuill et al. 2007). PK-2 directly activated 
magnocellular and parvocellular neurones of the PVN and this activation was inhibited 
with a PK-2 inhibitor in rats (Yuill et al. 2007).  
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Prokineticins (PKs): novel hypothalamic regulators of appetite and placental 
angiogenesis 
 
Prokineticin 2 is abundantly expressed in the suprachiasmatic nucleus of the 
hypothalamus. The expression of PK-2 mRNA falls markedly during fasting and the 
ICV administration of PK-2 to rats potently reduces food intake (Gardiner et al. 2010). 
Further evidence for the physiological role of PK-2 in the regulation of food intake 
comes from the increase in food intake which occurs following the ICV administration 
of an anti-PK-2 antibody to rats (Gardiner et al. 2010). The PK-2 receptor is highly 
expressed in the ARC and the direct injection of PK-2 into the ARC reduces food 
intake. Part of the anorectic effect of PK-2 is mediated through the melanocortin 
system. Ex vivo, PK-2 potentiates the release of α-MSH from hypothalamic explants. 
Furthermore, in vivo, ICV administration of the MC4R antagonist, agouti, blocks the 
anorectic effect of PK-2. The peripheral administration of PK-2 to mice reduces food 
intake and furthermore, the chronic peripheral administration of PK-2 reduces body 
weight in both lean and obese mice. This demonstrates both that tachyphylaxis to the 
anorectic effect of PK-2 does not occur with repeated administration and that obese 
animals remain sensitive to the effects of PK-2. Both these findings identify the PK-2 
signalling system as a potential novel therapeutic target for the treatment of obesity.  
However PK-2 is predominantly expressed centrally within the CNS, where as PK-1 is 
expressed peripherally including within the gut. Both PK’s stimulate the PKRs, albeit 
PK-2 with greater affinity during in vitro receptor binding studies. Therefore it is 
possible that PK-1 may represent a novel gut hormone, which interacts with PKR’s 
located centrally within the hypothalamus to mediate an anorectic effect on appetite. If 
this were to be the case then PK-1 may represent a more suitable target for therapeutic 
interventions, as these would need to be administered peripherally. In this thesis I have 
 42 
investigated the role of prokineticin-1 on appetite in rodents and also compared the 
effects to prokineticin-2. I also determine the changes in plasma levels of prokineticin-1 
in humans following satiation to establish the potential physiological relevance of 
prokineticin-1 as an anorectic gut hormone.  
 
Prokineticin-1 is also a potent angiogenic mitogen on endocrine vascular epithelium and 
hence it is also known as ‘Endocrine Gland derived-Vascular Endothelial Factor’. 
Placental angiogenesis plays an important role in placental function and risk of 
pregnancy complications such as miscarriage. I therefore hypothesised that prokineticin-
1 is a biomarker of pregnancy complications in humans. In this thesis, I have measured 
circulating levels of PK-1 found in pregnancy and correlated these with the occurrence 
of pregnancy complications. I have also compared the utility of PK-1 with other 
potential novel markers of pregnancy complications. Together this body of work 
investigates the potential physiological roles of PK-1. 
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Chapter 2 
 
Role of PK-1 in                   
Appetite Regulation 
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Introduction 
 
Both PK1 and PK2 stimulate the PKRs. Prokineticin-2 is predominantly expressed 
centrally within the CNS, whereas prokineticin-1 is expressed peripherally including within 
the gut. PK-2 administration has been shown to potently suppress food intake in rodent 
models as detailed below.  
Hypothalamic PK-2 expression is significantly reduced by 45% in rats fasted for 12 or 24 h 
when compared with ad libitum fed rats (Gardiner et al. 2010). ICV PK-2 administration to 
ad libitum fed male rats significantly reduced food intake during the first hour following 
administration at doses greater than 0.05 nmol/rat at the beginning of the dark phase 
(Gardiner et al. 2010). Indeed doses of 0.15-1.5 nmol/rat maximally reduced food intake by 
85% when compared with vehicle treated rats (Gardiner et al. 2010). A reduction in food 
intake over the first hour was also seen in rats fasted for 24 h following injection with ICV 
with 0.15-4.5 nmol/rat of PK-2 in the early light phase (Gardiner et al. 2010). PK-2 reduced 
the number of feeding episodes and did not result in abnormal behavioural patterns 
suggesting a specific effect on appetite. Furthermore, there was no alteration in energy 
expenditure as assessed by O2 consumption and additionally pair-fed animals lost a similar 
amount of weight to PK-2 treated animals, suggesting that weight loss occurred through a 
direct effect on appetite (Gardiner et al. 2010). 
Additionally, ICV administration of a PK-2 blocking antibody to satiated rats at the 
beginning of the light phase increased food intake (Gardiner et al. 2010). ICV 
administration of PK2 resulted in a significant increase in c-fos immuno-reactivity in the 
supraoptic nucleus (SON), arcuate (ARC), paraventricular nucleus (PVN), and anterior 
hypothalamic area (AHA), but not in the ventromedial hypothalamus (VMH), dorosmedial 
hypothalamus (DMN), suprachiasmatic nucleus (SCN), or lateral hypothalamic area (LHA) 
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(Gardiner et al. 2010). Furthermore co-localisation studies confirmed that ICV PK-2 
activated arcuate (ARC) POMC neurons (Gardiner et al. 2010).  
Intraperitoneal (IP) injection of 20 nmol/kg of PK-2 at the beginning of the dark phase 
significantly reduced food intake in rats (Gardiner et al. 2010). IP injections of 7, 20, 60, 
180, or 540 nmol/kg dose-dependently reduced food intake in C57BL/6 mice (Gardiner et 
al. 2010).  The highest dose of PK2 administered (540 nmol/kg) resulted in a 20% 
reduction in 24-h food intake (Gardiner et al. 2010). Twice daily IP injection of 180 
nmol/kg of PK-2 for 5 days in lean mice significantly decreased cumulative food intake and 
body weight with no evidence of tachyphylaxis (Gardiner et al. 2010). Importantly, PK-2 
was equally effective in DIO (diet induced obese) mice, which has important implications 
for therapeutic use (Gardiner et al. 2010). 
IP administration of 540nmol/kg of PK-2 to C57Bl/6 mice significantly increased c-fos-like 
immuno-reactivity in the dorsal motor vagal nucleus (DMV) in the brainstem, but not in 
other areas of the brainstem or hypothalamus (Beale et al. 2013). Peripheral PK-2 
administration retains its anorectic effects in PKR-2 knock-out mice, but not in PKR-1 
knock out mice (Beale et al. 2013). This suggests that the anorectic effects of peripheral 
PK-2 occur via PKR-1 in the brainstem (Beale et al. 2013). PK2 administered at 60 
nmol/kg/h or 120 nmol/kg/h by continuous subcutaneous (SC) infusion to DIO mice 
significantly reduced body weight gain between days 1 and 13 post-surgical implantation of 
an osmotic minipump when compared with vehicle treated controls (Beale et al. 2013). 
Mice pair-fed to each dose of PK2 lost a similar amount of weight to those administered 
PK2, suggesting that these effects occurred via alterations in food intake alone (Beale et al. 
2013). 
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Thus, PK2 has potent anorectic effects and both PK1 and PK2 stimulate the PKRs. Since 
PK-1 is distributed peripherally (especially in the gut), one could hypothesise that PK-1 
may be a physiological gut hormone which inhibits food intake. However no studies to date 
have determined the effects of PK-1 in food intake.  In this chapter I will investigate the 
role of PK-1 on appetite regulation and compare this with PK-2.  
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Hypothesis and aims 
 
Hypothesis 
PK-1 is a gut hormone acting as a physiological inhibitor of food intake. 
 
Aims 
1. Comparison of ICV PK-1 and PK-2 at doses of 15-150 pmol between 0-24hrs 
during dark phase in adult male Wistar rats  
2. Comparison of ICV PK-1 and PK-2 at doses of 15-1500 pmol between 0-24hrs 
during dark phase in adult male Wistar rats  
3. Comparison of IP PK-1 and PK-2 at doses of 20-540 nmol/kg between 0-24hrs 
4. Serum levels of PK-1 and food intake at 1 hour following administration of IP PK-1 
7 nmol/kg on food intake in mice 
5. Expression of PK-1 mRNA in the stomach of Fed and Fasted mice 
6. Assessment of circulating levels of PK-1 in humans in fasted and fed states 
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Material and methods 
 
1. Effect of ICV administration of 15, 50, 150 pmol of PK-1 during Dark Phase in 
male Wistar rats 
Materials 
 
PK-1 was purchased from PeproTech Ltd. (New Jersey, USA). Cannulation materials were 
purchased from Plastics One, Inc. (Roanoke, VA, USA).  NDP-melanocyte stimulating 
hormone (NDP-MSH) was obtained from by Bachem (St Helen’s, UK). 
 
Rodent models 
 
Male Wistar rats 
 
Male Wistar rats (specific pathogen free; Charles River, Margate, UK) weighing between 
250-300g were maintained in individual cages under controlled temperature (21-23 °C), 
light (12:12 light-dark cycle on at 0700 h), with ad libitum access to food (RMI diet, SDS 
UK Ltd) and water.  All animal procedures were conducted under the British Home Office 
Animals (Scientific Procedures) Act 1986 (Project Licence 70/5516). 
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Intracerebroventricular (ICV) cannulation and injections 
 
Male Wistar rats were anaesthetised with an intraperitoneal (IP) injection of a mixture of 
xylazine (12mg/kg; Rompun, Bayer UK Ltd, Bury St Edmunds, UK) and ketamine 
(60mg/kg; ketalar, Parke-Davis, Pontypool, UK).  Prophylactic antibiotics, flucloxacillin 
(37.5 mg/kg) and amoxicillin (37.5 mg/kg) were administered prior to surgery. 
The rat was placed in a stereotaxic frame (David Kopf Instruments, supplied by Clark 
Electromedical Instruments, Reading, UK), with the incisor bar positioned 3mm below the 
interaural line.  The surgical area was cleaned with 10% (weight/volume) bovidine-iodine 
solution (Betadine, Seton Healthcare, Oldham, UK). A longitudinal incision of 
approximately 1.5 cm was made in the skin over the vertex of the skull and the periosteum 
removed from the underlying bone. A permanent 22-gauge stainless steel cannula (Plastics 
One Inc., Roanoke, VA, USA.) was stereotactically placed 0.8mm posterior to bregma in 
the midline and a hole was made in the skull using an electric drill at this position to 
accommodate the cannula.  The cannula was then stereotactically implanted 6.5 mm below 
the surface of the skull into the third cerebral ventricle.  The cannula was secured and the 
wound sealed with dental cement (Associated Dental Products Ltd., Kemdent Works, 
Swindon, U.K.) anchored to three stainless steel jewellers’ screws secured into the cranium.  
The co-ordinates of the cannula position were calculated using the atlas of Paxinos and 
Watson (Paxinos and Watson, 1998). 
After surgery, a plastic topped wire stylet (Plastics One Inc.) was inserted into the cannula 
to prevent occlusion. The rats were given 0.9% sodium chloride IP (5ml/rat) for circulatory 
support and given subcutaneous (SC) buprenorphine 45 μg/kg (Schering-Plough Ltd. 
Welwyn Garden City, U.K.) for postoperative analgesia.  Following a 7 day recovery 
period the animals were handled and weighed on a daily basis.  Only animals with correct 
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cannula placement, as confirmed by a sustained drinking response to ICV angiotensin II 
(50ng /rat), were included in the studies. Animals were acclimatised to the injection process 
by a subsequent saline injection. Peptides were dissolved in 0.9% saline and administered 
in a 5 l volume via a stainless steel injector projecting 1 mm beyond the tip of the cannula. 
The injector was connected by polyethylene tubing (inner diameter, 0.5 mm; outer 
diameter, 1mm) to a Hamilton syringe (Reno, NV, USA) in a syringe pump set to dispense 
5l solution/min. 
 
To determine whether PK-1 affects food intake during the natural rat feeding period of 
these nocturnal animals, ad-libitum fed rats (n=6-8 per group) were ICV injected with 0.9% 
saline or PK-1 or PK-2 at 15, 50 or 150 pmol immediately before the onset of dark phase 
(19:00). NDP-MSH at 3nmols was injected as a positive control (n=3). Rats were returned 
to their home cages with a pre-weighed amount of chow and free access to water. The 
remaining food was reweighed at 1, 2, 4, 8 and 24 h post-injection.  
 
 
 
2. Effect of ICV administration of 15, 150 and 1500 pmol PK-1 
 
This study was conducted in the same manner as experiment 1, but the doses of PK-1 and 
PK-2 injected were of a greater dosing range (15, 150 and 1500 pmol) in order to determine 
a more complete dose response of the effect of ICV administered PK-1 on nocturnal food 
intake in rats. 
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3. Comparison of peripheral administration of IP PK-1 and PK-2 at doses of 20, 60 
and 540 nmol/kg between 0-24hrs in male C57BL/6 mice. 
 
This experiment was performed in order to assess the effects of peripheral administration of 
PK-1 on food intake in mice. 
 
Materials 
 
PK-1 was purchased from PeproTech, Inc. (New Jersey, USA), Oxyntomodulin was 
obtained from Peninsula Laboratories (RnDSystems, UK) and NDP-αMSH was purchased 
from Sigma-Aldrich (Dorset, UK). 
 
 
C57BL/6 mice 
 
Male C57BL/6 mice (specific pathogen free; Harlan, UK) weighing between 20-30g were 
maintained in individual cages under controlled temperature (21-23°C) and light (12:12 
light-dark cycle on at 0700 h) with ad libitum access to food (RMI diet, SDS UK Ltd) and 
water.   
All animal procedures were conducted under the British Home Office Animals (Scientific 
Procedures) Act 1986 (Project Licence 70/5516 and 70/6402).  All animals were 
randomised by weight in to treatment groups. 
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IP injections 
 
Animals were handled daily and acclimatised to the injection procedure by two saline IP 
injections administered during the week before the study. On the day of the study, peptides 
were dissolved in 10% water and 90% saline (0.9%) immediately prior to injection.  The 
injection volume was 0.1 ml per mouse.  
I investigated the dosing range and time-frame of action on food intake in male mice at 
doses of 20, 60 and 540 nmol/kg over the first 24 hours following IP injection and 
compared this with equimolar doses of PK-2. 
 
 
4. Effect of IP PK-1 7 nmol/kg for up to 1 hour in mice (n=6 per group). 
 
As the lowest dose of PK1 tested of 20 nmol/kg reduced 1 hour food intake by 
approximately 50% during the previous experiment, I went on to determine if a smaller 
dose of PK-1 of 7 nmol/kg could still reduce food intake, but by a smaller amount which 
might be expected physiologically if PK-1 is an endogenous anorectic gut hormone. This 
would allow me to determine plasma PK-1 levels by ELISA following PK-1 administration 
to assess the circulating levels of PK-1 required for its anorectic effects.   
 
To determine whether 7 nmol/kg of PK-1 effects food intake during the natural feeding 
period, ad-libitum fed mice (n = 6 per group) were injected IP immediately before the onset 
of the dark-phase (19:00) with either 0.9% saline or PK-1 at 7nmol/kg.  Mice were returned 
to their home cages with a pre-weighed amount of chow and free access to water.  The 
remaining food was reweighed at 1 hr post-injection as in experiment 3. 
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5. Determination of the effect of fasting on expression of PK-1 in the stomach of Fed 
and Fasted mice 
 
Whilst PK-2 has been shown to be localised to the central nervous system (CNS), PK-1 is 
predominantly expressed peripherally including within the gut. It is therefore reasonable to 
hypothesise that PK-2 may influence appetite in response to circadian rhythms centrally, 
whilst PK-1 is a gut hormone regulating appetite in response to food intake.   
If PK-1 was a physiological gut hormone regulating appetite in response to food intake, one 
might expect that expression of PK-1 in the stomach would be low during fasting, but 
would be increased in response to feeding. Therefore I investigated changes in PK-1 
expression with feeding in male C57BL/6 mice.  
 
Male C57BL/6 mice were either fed ad libitum (n=8) or fasted for 24 hours (n=12).  Mice 
were killed by decapitation and the brains removed.  The stomach was dissected out, snap 
frozen in liquid nitrogen and stored at -70°C. Total gut PK-1 mRNA expression determined 
by real-time quantitative PCR as described below.  
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Total RNA extraction 
 
Materials 
 
Lysis/Binding Solution 
64% Ethanol 
100% Ethanol 
Wash Solution-1 
Wash Solution-2/3 
Elution Solution (0.1mM EDTA) 
10x DNase-1 buffer 
DNase-1 (RNase-free) 
DNase Inactivation Reagent 
5M Ammonium Acetate 
Linear Acrylamide (5mg/ml) 
Glass Distilled Water (GDW) 
Method 
 
Total RNA was extracted using an RNAqueous®-4PCR kit (Applied Biosystems, 
California, USA) according to the manufacturer’s protocol.  Stomachs were homogenised 
in lysis/binding solution (750µl of lysis/binding solution per stomach).  An equal volume of 
64% ethanol was added and gently mixed.  The mixture was then placed in a filter cartridge 
and passed through the cartridge by centrifugation at 20,800 x g for one minute.  The flow-
through was disposed of and 700µl of wash solution-1 was then added to the filter 
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cartridge.  The wash solution was passed through the filter cartridge as described previously 
and the flow-through again discarded.  This step was repeated a further two times using 
wash solution-2/3 at a volume of 500µl each time.  The filter was then placed in a fresh 
collection tube and 50µl of elution solution, preheated to 70-80ºC, was added to the filter 
cartridge. The solution was passed through the cartridge into the collection tube by 
centrifugation at 20,800 x g for 30 seconds. 5µl 10x DNase 1 buffer and 1.1µl DNase 1 was 
then added to the collected solution and the mixture incubated at 37ºC for 25 minutes.  
Following this, 0.1 volumes of DNase inactivation agent was added, gently mixed and 
incubated for 1-2 minutes at room temperature. The mixture was then centrifuged for 1 
minute at 20,800 x g and the supernatant collected. The RNA solution was concentrated by 
adding 0.1 volumes of 5M ammonium acetate, 0.01 volumes of linear acrylamide and 2.5 
volumes 100% ethanol and incubating at -20ºC for at least one hour.  The mixture was then 
centrifuged at 20,800 x g for 15 minutes and the pellet resuspended in 20µl GDW (glass 
distilled water). The RNA concentration was determined spectrophotometrically. The RNA 
was diluted 1:100 in GDW and placed into a quartz cuvette. The absorbance was measured 
at 280nm (UV-160 spectrophotometer, Shimadzu, Kyoto, Japan).  The total amount of 
RNA recovered was calculated using the following formula: 
 
Concentration of RNA (µg/ml) = A260 x dilution factor x 40 
 
The RNA was then diluted in GDW accordingly.  RNA used for normalisation to 18S RNA 
was diluted to a concentration of 0.1µg/µl, whereas all other RNA samples were diluted to 
0.05µg/µl. 
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Reverse Transcription (RT) 
 
Reverse transcription of the extracted RNA was carried out in order to produce cDNA.  
 
Materials 
 
Mouse stomach RNA (at a concentration of either 0.1 or 0.5µg/ml) 
2x RT Master Mix (per 20µl reaction): 
 2µl 10x RT Buffer 
 0.8µl 25x dNTP mix (100mM) 
 2µl 10x RT Random Primers 
 1µl MultiScribe™ Reverse Transcriptase 
 4.2µl GDW  
GDW 
Method 
 
cDNA was synthesised from RNA using a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, California, USA) according to the manufacturer’s protocol.  10µl of 
2x RT master mix was pipetted to each well of a 96-well reaction well plate.  10µl of 
0.05µg/µl RNA sample was added to each well in triplicate and pipetted up and down twice 
to ensure thorough mixing.  RNA used for 18S RNA normalisation (at 0.1µg/µl) was first 
diluted 1:10 in GDW before adding to the reaction well plate.  The 96-well plate was sealed 
with aluminium film and loaded into a thermal cycler under the following conditions: 1) 
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25ºC for 10 minutes, 2) 37ºC for 120 minutes, 3) 85ºC for 5 seconds, and 4) 4ºC until 
transferred to -20ºC for storage.  
Real-time quantitative PCR 
 
Materials 
 
TaqMan Universal PCR Master Mix (Applied Biosystems) 
20x TaqMan Gene Expression Assay (Applied Biosystems) 
cDNA synthesised from mice stomach RNA 
 
Method 
 
10µl of TaqMan Universal PCR Master Mix, 1µl TaqMan Gene Expression Assay (18S 
RNA primer assay ID: 4310893E-0608033, PK-1 primer assay ID-4351372) and 7µl GDW 
was added to each well in a 384-well reaction plate. 2µl of cDNA (approximately 50ng) 
was then added in triplicate to each well and pipetted up and down twice to ensure thorough 
mixing. The 384-well reaction well plate covered with optical adhesive film and 
centrifuged briefly to minimise air bubbles. The reaction well plate was then loaded into a 
quantitative PCR machine (7900HT quantitative PCR machine, Applied Biosystems, 
California, USA) under the following conditions: 1) 50ºC for 2 minutes, 2) 95ºC for 10 
minutes, 3) 95ºC for 15 seconds, 4) 60ºC for 1 minute (steps 3) and 4) were repeated for 40 
cycles).  Gene expression was quantified relative to 18S RNA and analysed using the 2
-C
T 
method (Livak and Schmittgen, 2001). 
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6. Human plasma PK1 levels fed fasted 
 
In order to investigate whether PK-1 is a physiological gut hormone in humans, I 
investigated whether plasma levels of PK-1 would change with feeding in humans.  
If PK-1 was a physiological gut hormone then it would be expected that plasma PK-1 levels 
would be low during fasting and rise following food intake signalling satiety.  
Therefore to investigate whether plasma levels of PK-1 are altered by feeding, 4 healthy 
men and 4 healthy women, aged 19-34 years old, were recruited and asked to fast from 
10pm (only having sips of water thereafter). They attended the clinical research unit at 
10am the following morning and were intravenously cannulated and fasting blood was 
sampled. At each time point 6mls of blood was taken into lithium heparin tubes each 
containing 200 µls of trasylol (see Table 3). The samples were immediately spun at 6,400 x 
g for 4 minutes. Plasma was separated into 3 eppendorfs and immediately frozen at -20
○
C 
until analysis. Two packets of macaroni cheese were prepared and participants were 
allowed to eat and drink until satiated from time 0 (see Table 4 for details of food used for 
ingestion). All participants ate at least one packet of macaroni cheese and some ate 2 
packets. Blood was sampled at 15 minutely intervals until 2 hours following commencing 
eating at time 0 (see Table 3).  
Plasma PK-1 was measured using a commercially available ELISA kit (ABNOVA) as 
described below.  
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Table 3: Study Protocol for measurement of plasma PK-1 levels in humans.  
 
Participants were intravenously cannulated at Time -30. Participants were asked to start 
eating from Time 0. Plasma was measured every 15 minutes for 2 hours. 
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Time point (min) Time  
Blood 
(6ml) Well? 
Baseline Sampling     -30       
Start Eating Food          0 
   15 
   30       
45 
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Table 4: Details of contents of Macaroni Cheese packets used to induce satiety in 
humans (Sainsbury’s Ltd, UK)  
A mature Cheddar cheese sauce on a bed of macaroni pasta topped with grated mature 
Cheddar cheese 400g pack.  
 
Typical values per 100g per pack 
Energy 201  kcal 780  kcal 
Energy 844  kj 3266  kj 
Protein 8.50  g 32.90  g 
Carbohydrate 20.57  g 79.61  g 
Sugars 1.13  g 4.37  g 
Fat 9.13  g 35.33  g 
Saturates 5.03  g 19.47  g 
Fibre 1.50  g 5.81  g 
Sodium 0.24  g 0.929  g 
 
Ingredients: 
Water, milk, mature Cheddar cheese (20%), durum wheat semolina, pasteurised free range 
egg, single cream, wheat flour, rapeseed oil, cornflour, mustard flour, salt, sugar, white 
pepper, acidity regulator citric acid, turmeric 
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Methods: Plasma PK-1 measurement by ELISA kit (ABNOVA) 
 
Reconstitution of the human PK-1 standard:  
One tube of 10,000 pg of standard was used to generate standards by dilution. 
• 10,000 pg/ml of human PK-1 standard solution: 10,000 pg vial of PK-1 standard was 
reconstituted using 1 ml of sample diluent buffer. The standard was kept at room 
temperature for 10 minutes and thoroughly mixed. 
• 1,000 pg/ml of human PK-1standard solution: 0.1 ml of the above 10,000 pg/ml PK-1 
standard solution was added into 0.9 ml sample diluent buffer and thoroughly mixed. 
• 500 pg/ml - 15.6 pg/ml of human PK-1 standard solutions: 6 Eppendorf tubes were 
labelled with 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.2 pg/ml, 15.6 pg/ml, 
respectively. 0.3 ml of the sample diluent buffer was aliquoted into each tube. 0.3 ml of the 
above 1000pg/ml PK-1 standard solution was added into 1st tube and thoroughly mixed. 
0.3 ml from 1st tube was transferred to 2nd tube and thoroughly mixed. 0.3 ml from the 
2nd tube was transferred to the 3rd tube and mixed, and so on. 
 
0.1 ml per well of the 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.2 
pg/ml, 15.6  pg/ml human PK-1 standard solutions were aliquoted into the pre-coated 96-
well plate. 0.1ml of each sample of human plasma was added to each empty well.  
The plate was sealed with a cover and incubated at 37°C for 90 minutes. 
The cover was then removed, plate content discarded, and blotted onto paper towels. The 
wells were not allowed to completely dry at any time.  
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Then 0.1 ml of biotinylated anti-human PK-1 antibody working solution was added into 
each well using a multichannel pipette and the plate was incubated in the dark at 37°C for 
60 minutes.  
The plate was washed 3 times using an automated washer: The plate was blotted onto paper 
towels or other absorbent material. 
Preparation of 0.01 M PBS wash buffer: 
8.5 g sodium chloride, 1.4 g Na2HPO4 and 0.27 g NaH2PO4.2H20 were added to 1000 ml 
distilled water and pH adjusted to 7.2-7.6.  
0.1 ml of prepared ABC working solution (secondary antibody) was added into each well 
and the plate incubated at 37°C for 30 minutes. 
The plate was then washed 5 times with 0.01 M PBS, with a soak step of 90 seconds.  
90 μl of prepared TMB colour developing agent was added into each well using a 
multichannel pipette and the plate incubated at 37°C in dark for 25 minutes.  
Shades of blue can then be seen in the wells with the four most concentrated human PK-1 
standard solutions; whereas the other wells show no obvious colour. 
0.1 ml of prepared TMB stop solution was then added using multichannel pipette into each 
well. The colour then changes to yellow immediately. 
O.D. absorbance was read at 450nm in a microplate reader within 30 minutes of adding the 
stop solution. 
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1. Results: 
 
ICV administration of PK-1 administration significantly reduced food intake during the 
first 24 hrs when compared with saline administration (see Figure 4).  Doses of 50 and 150 
pmol of PK-1 similarly reduced food intake by 75% during the first hour following 
administration during the dark phase when compared with the saline group. This reduction 
in food intake was similar to that seen following PK-2 administration. Interestingly, PK-1 
also significantly reduced food intake during the light phase during 8-24 hrs following ICV 
administration. ICV administration of PK-1 was at least as effective as equimolar doses of 
PK-2 at reducing food intake. There was a tendency for the higher doses tested of 50 and 
150 pmol of PK-1 and PK-2 to rapidly and immediately reduce food intake during the first 
hour following administration to a greater degree than the lower 15 pmol dose. The lower 
15 pmol dose appears to have a slower onset of action and did not significantly reduce food 
intake until 2-8 hrs following administration than higher doses tested (see Figure 4).  
The reduction in food intake during the first 24 hrs following ICV PK-1 at all three doses 
tested between 15 and 150 pmols was similar at approximately 60%, therefore I went on to 
investigate whether higher doses of PK-1 were able to reduce food intake to an even greater 
degree in experiment 2.  
 
 64 
Figure 4: Comparison of ICV PK-1 and PK-2 at doses of 15, 50, 150 pmol between 0-
24hrs during dark phase in adult male Wistar rats (n=6-8/group). 
NDP-MSH 3nmol was used as a positive control. Groups were compared by one way 
ANOVA with post hoc Dunnet's test against Saline Group. *P<0.05,**P<0.01,***P<0.001. 
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2. Results: 
 
ICV PK-1 or PK-2 administration significantly reduced food intake during the first hour 
following administration down to 22% following 1500 pmol, which was greater than the 
reduction seen following 150 pmol (see Figure 5).  
However, there were not significant reductions in food intake beyond this time frame.  
This may partly have been due to the saline group not having eaten as much food as they 
would normally do (as in experiment 1), making some of the reductions less significant in 
comparison to saline.  
 
Results from study 1 and 2 suggested that PK-1 appears to have similar efficacy to PK-2 
when administered centrally. If PK-1 were to be administered as a therapeutic to target 
obesity, then it would be administered peripherally. Hence it was important to study the 
peripheral effects of PK-1 administration on food intake. As the cost of PK-1 is very high, 
and larger doses are required for peripheral administration, peripheral experiments were 
carried out in mice rather than rats.  
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Figure 5: Comparison of ICV PK-1 and PK-2 at doses of 15, 150 and 1500 pmol 
between 0-24hrs during dark phase in adult male Wistar rats (n=7-10 per group).  
Oxyntomodulin (OXM) 3 nmol was used as a positive control (n=4). Groups were 
compared by one way ANOVA with post hoc Dunnet’s test with Saline Group.  
* P<0.05, **P<0.01, ***P<0.001. 
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3. Results: 
Doses of 20 and 60 nmol/kg of both PK-1 and PK-2 similarly reduced food intake over the 
first hour by approximately half when compared with saline (see Figure 6). Impressively a 
dose of 540 nmol/kg of either PK-1 or PK-2 reduced food intake by over 90% during the 
first hour. However the effect on food intake had worn off by 4 hrs post administration, 
with no reduction in food intake observed between 4 and 24 hrs post administration. Hence 
only the highest dose of PK-1 resulted in a significant reduction over the first 24hrs 
following administration. 
This was confirmed by observing the food intake over time, such that food intake was 
similar to saline after 8 hours following administration (see Figure 7). Only the highest 
dose of 540 nmol/kg of PK-1 or PK-2 resulted in a fall in body weight at 24 hrs (-0.66 g 
following the highest dose of PK-2 at 24 hours) (see Figure 8).  
Importantly this demonstrates that both PK-1 and PK-2 are able to reduce food intake in 
mice following peripheral administration. Furthermore the highest doses of both peptides 
resulted in reduction in body weight at 24 hrs following administration. Given the short 
duration of action it would seem likely that more frequent administration may have more 
profound effects on food intake over a prolonged period.  
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Mean ±SEM is shown for food intake and compared by one way ANOVA with post hoc 
Dunnet’s test *P<0.05, **P<0.01, ***P<0.001. Separate graphs are shown for food intake 
between 0-1 hr, 1-2hr, 2-4hr, 4-8hr, 8-24hr and 0-24hr.  
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Figure 6:  Comparison of IP PK-1 and PK-2 at doses of 20-540 nmol/kg between 0-
24hrs in male C57BL/6 mice (n=6 per dosing group). 
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Mean ±SEM of cumulative food intake expressed as a percentage of that seen following 
control saline administration is shown and compared by Two way ANOVA with post hoc 
bonferrroni correction.  *P<0.05, **P<0.01, ***P<0.001. 
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Figure 7: Comparison of IP PK-1 and PK-2 at doses of 20-540 nmol/kg between 0-24hrs 
in male C57BL/6 mice (n=6 per dosing group).  
 70 
 
 
 
Mean ±SEM of change in body weight from baseline until 24hrs following 20, 60 and 540 
nmol/kg of PK-1 or PK-2 is shown. 
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Figure 8: Change in Body weight in grams over 24 hours after doses of 20, 60 and 
540 nmol/kg of PK-1 or PK-2 in male C57BL/6 mice.  
 71 
4. Results: 
 
IP injection of PK-1 reduced food intake by just over 50% over the first hour following 
administration (see Figure 9). I measured the serum PK-1 levels by a commercial ELISA 
kit (Peprotech) during this experiment. Serum PK-1 levels were highest at 20 minutes 
following injection at 40 pg/ml, before falling to 10 pg/ml at 60 minutes following 
administration (see Figure 10).  
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Figure 9: Effect of IP PK1 7 nmol/kg for up to 1 hour in mice (n=6 per group) on food 
intake over the first hour in Male C57BL/6 mice. 
No significant difference was seen following comparison by unpaired Students’ t test 
although mean food intake was reduced by more than 50%.  
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Figure 10: Serum PK-1 levels during the first hour following injection with 7 nmol/kg 
of PK-1 given IP to male C57BL/6 mice.  
PK-1 was measured by Peprotech ELISA kit in pg/ml (n=6 per group). Serum levels of PK-
1 peaks at 20 minutes following administration of exogenous PK-1 in rodents suggesting 
that PK-1 has a short half-life.  
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5. Results:  
 
Mean ±SEM of expression of PK-1 mRNA was higher in fasted mice (0.83 ±0.13) when 
compared with fed mice (0.58 ±0.07), although this was not statistically significant when 
compared by Mann Whitney test (P=0.15), this would be consistent with the pattern of 
expression which would be expected if PK-1 was a physiological gut hormone, being low 
in fasted mice and increasing with food intake to signal satiety to the appetite centres in the 
brain (see Figure 11).  
It is possible that the results of this experiment would be significant should a larger sample 
size be employed. 
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Figure 11: Expression of PK-1 in the stomach of male C57BL/6 mice in fasting (n= 12) 
and in fed state (n=8).  
Mean ±SEM of each group is shown. Groups were not significantly different when 
compared by Mann Whitney test (P=0.15). 
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6. Results:  
 
Plasma PK-1 levels varied widely between different individuals. The standard curves for 
each plate during the assay were reasonably straight suggesting that poor assay technique is 
unlikely to observation (see Figure 12). 
One female participant in the study had a plasma PK-1 level of approximately 400 pg/ml 
and a further male paritcipant had a PK-1 level between 100 and 200 pg/ml. However the 
majority of patients had levels below 100 pg/ml (see Figure 13).  
There was no significant difference in plasma PK-1 levels following feeding and certainly 
no significant rise in PK-1 levels following feeding (see Figure 14).  
Some participants had much higher baseline levels of PK-1 than other participants, 
suggesting the influence of other unidentified dominant factors beyond satiety on PK-1 
levels. Another possibility for high levels of PK-1 seen in some individuals is the presence 
of other interfering substances interacting with the performance of the assay. Although the 
highest level was seen in a female there was no clear sex differential between participants.  
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Figure 12: Standard Curves used for the interpolation of plasma PK-1 levels.  
 
Standard concentrations of 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.2 
pg/ml, 15.6 pg/ml of human PK-1 standard solutions were aliquoted into the pre-coated 96-
well plates and OD (optical density) Absorbance was read at 450 nm in a microplate reader. 
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Figure 13: Circulating plasma PK1 levels in humans whilst fasted and following 
feeding.  
4 female and 4 male participants were fasted for 12 hours and then were asked to start 
eating at T=0. Plasma Pk-1 levels were then assessed for 120 minutes. Individual plasma 
prokineticin-1 (PK-1) levels as measured by ELISA (Abnova) for each participant is 
shown.  
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Figure 14: Change in circulating plasma PK-1 levels in humans whilst fasted and 
following feeding. 
 
4 female and 4 male participants were fasted for 12 hours and then were asked to start 
eating at T=0. Plasma prokineticin-1 (PK-1) levels were then assessed for 120 minutes. 
Mean ±SEM of change in plasma PK-1 levels from fasting levels as measured by ELISA 
(Abnova) is shown. There was no significant difference in PK-1 levels as analysed by two 
way ANOVA.  
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Discussion: 
 
In this chapter I have investigated the role of PK-1 as a potential novel gut hormone and I 
have compared its anorectic effects to those observed with PK-2.  
Central administration of PK-1 administration significantly reduced food intake during the 
first 24 hrs when compared with saline administration. Doses of 50 and 150 pmol of PK-1 
similarly reduced food intake by 75% during the first hour following administration during 
the dark phase when compared with the saline group. This reduction in food intake was 
similar to that seen following PK-2 administration.  
Central administration of PK-1 was at least as effective as equimolar doses of PK-2 at 
reducing food intake. There was a tendency for the higher doses tested of 50 and 150 pmol 
of PK-1 and PK-2 to reduce food intake during the first hour following administration to a 
greater degree than the lower 15 pmol dose, whilst conversely, there was a trend for the 
lower 15 pmol dose to have a slower onset of action reducing food intake significantly 
between 2-8 hrs following administration.  
The reduction in food intake during the first 24 hrs following central PK-1 at all three doses 
tested between 15 and 150 pmols was similar at approximately 60%, therefore I went on to 
investigate whether higher doses of PK-1 was able to reduce food intake to a greater 
degree.  
Central PK-1 or PK-2 administration significantly reduced food intake during the first hour 
following administration down to 22% following 1500 pmol, which was greater than that 
seen following 150 pmol. However there were not significant reductions in food intake 
beyond this time frame suggesting a short duration of action.  
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PK-1 had a similar efficacy to PK-2 when administered centrally. However, if PK-1 were to 
be administered as a therapeutic to target obesity, then it would be important to study the 
peripheral effects of PK-1 administration. As the cost of PK-1 is very high, and larger doses 
are required for peripheral administration, peripheral experiments were carried out in mice. 
Peripheral IP injection of PK-1 reduced food intake by just over half during the first hour 
following administration. I also measured the serum PK-1 levels by a commercial ELISA 
kit (Peprotech) in mice. Serum PK-1 levels were highest at 20 minutes following injection 
at 40 pg/ml, before falling to 10 pg/ml at 60 minutes following administration suggesting a 
short half life of approximately half an hour. I went on to investigate the dosing range and 
time frame of action on food intake in male mice at doses of 20, 60 and 540 nmol/kg over 
the first 24 hours following IP injection and compared this with equimolar doses of PK-2. 
Doses of 20 and 60 nmol/kg of both PK-1 and PK-2 similarly reduced food intake over the 
first hour by approximately half when compared with saline. Impressively a dose of 540 
nmol/kg of either PK-1 or PK-2 reduced food intake by over 90% during the first hour. 
However the effect on food intake had worn off by 4 hrs post administration, with no 
reduction in food intake observed between 4 and 24 hrs post administration. Hence only the 
highest dose of PK-1 resulted in a significant reduction over the first 24hrs following 
administration.  
Importantly this shows that both PK-1 and PK-2 are able to reduce food intake in mice 
following peripheral administration. Furthermore, the highest doses of these peptides 
resulted in a reduction in body weight at 24 hrs following administration highlighting its 
potential as a target for the development of anti-obesity therapeutics. Given the short 
duration of action it would seem reasonable that more frequent administration may have 
more profound effects on body weight over a longer period and similar experiments with 
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PK-2 have suggested that tachyphylaxis to the prokineticins with repeated administration 
does not occur.  
 
PK-1 expression was also lower in the stomachs of fasted mice although this finding did 
not achieve statistical significance. This would be consistent with the pattern of expression 
which would be expected if PK-1 was a physiological gut hormone, being low in fasted 
mice and increasing with food intake to signal satiety to the appetite centres in the brain.  
 
If PK-1 was a physiological gut hormone then it would be expected that plasma PK-1 levels 
would be low during fasting and rise following food intake signalling satiety. However I 
was not able to demonstrate a clear effect on circulating PK-1 levels in humans following 
feeding. Possible reasons for not seeing a rise in plasma PK-1 levels may be due to 
difficulties in measuring circulating PK-1 with current commercially available ELISA kits, 
as many participants had levels which were towards the lower end of the sensitivity of the 
assay. However even participants with higher endogenous levels did not show a clear effect 
on PK-1 following feeding (see Figure 13). The most likely possibility is that other 
unidentified factors may influence plasma PK-1 levels to a greater degree than those seen 
following feeding.  
 
In summary, I have demonstrated that both central and peripheral administration of PK-1 
potently reduces food intake and that expression of PK-1 levels in the stomachs of mice 
change in manner consistent with that of a physiological gut hormone. PK-1 therefore 
represents a novel target for the development of anti-obesity therapies.  
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Chapter 3 
 
Prokineticin-1 and other 
markers of 
complications of pregnancy 
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Introduction:  
 
The commonest and perhaps the most distressing of pregnancy complications is 
miscarriage. Miscarriage occurs with a cumulative risk of miscarriage of 20% by 20 weeks 
of gestation (Ammon Avalos et al. 2012). Miscarriage occurs most commonly in early 
pregnancy with a weekly miscarriage rate of >20 miscarriages per thousand woman-weeks 
up to 12 weeks of gestation, falling sharply thereafter down to a weekly miscarriage rate of 
only 1 miscarriage per 1000 woman-weeks between 16-20 weeks (Ammon Avalos et al. 
2012). Indeed most early miscarriages may not even be clinically apparent, with many 
pregnancies being lost within the first week after conception prior to implantation being 
established and many more during the following week prior to the start of the next 
menstrual cycle. Hence 6 in 7 miscarriages are clinically silent, occurring within the first 2 
weeks of conception and may not result in delay of the next menstrual cycle (see Figure 15) 
(Macklon et al. 2002). As patients are not scheduled for any routine antenatal appointments 
until their antenatal booking visit, which usually occurs after 8 weeks of pregnancy, it can 
be difficult to screen for miscarriage during the time when it is most prevalent (prior to 8 
weeks of pregnancy). After 12 weeks of pregnancy, approximately 4% of pregnancies will 
still result in miscarriage (Ammon Avalos et al. 2012).   
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Figure 15: Outcome of Conceptions 
Only 30% of conceptions result in live births and 60% of pregnancy loss is ‘subclinical’, 
occurring prior to the next period being delayed (within the first 2 weeks following 
conception). In fact only 1 in 7 miscarriages are clinically apparent occurring after 2 weeks 
post conception (adapted from Macklon et al. 2002). 
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Recurrent Pregnancy Loss (RPL) 
 
Recurrent pregnancy loss (RPL), where miscarriage occurs in 3 or more consecutive 
pregnancies, occurs in ~1% of fertile couples trying to conceive and is termed ‘early’ if this 
occurs before 12 weeks of gestation. Chromosomal abnormality in the miscarried embryo is 
present in up to 70% of early pregnancy losses in the first trimester, but in only 20% when 
the pregnancy loss is between 13 and 20 weeks of gestation (Tang et al. 2010). Abnormal 
karyotype is an important positive prognostic indicator for women with recurrent 
pregnancy loss, with a more than 75% chance of a successful outcome with a subsequent 
pregnancy. Despite a wide range of investigations no cause is found in 50% of cases (see 
table 5). However the prognosis following RPL is good with over 75% subsequently 
achieving a live birth (Tang et al. 2010).  
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Table 5: Cause of early Recurrent Pregnancy Loss and Risk factors for 
Miscarriage.  
Causes adapted from (Tang et al. 2010) and risk factors for miscarriage adapted 
from (Campbell et al. 2011). 
 
Causes of early Recurrent Pregnancy Loss Risk Factors for Miscarriage 
Parental and foetal Chromosomal abnormalities Increased Maternal Age 
Structural / congenital Uterine abnormalities ‘Risky’ Alcohol use 
Autoimmune disease E.g. anti-phospholipid syndrome Sexually transmitted infection 
Increased Maternal Immunity                                                           
E.g. increased Natural Killer cells 
 
Thrombophilia E.g. Factor V Leiden  
Endocrinological disorders                                                                                                
E.g. Polycystic ovarian syndrome, untreated Diabetes mellitus 
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The placenta  
 
Two thirds of miscarriages are attributed to defective placentation (Kaitu'u-Lino et al. 
2012). The placenta is the organ which allows the developing foetus to safely interact with 
the maternal blood system for gaseous exchange, nutrient provision and waste disposal. The 
word ‘placenta’ originates from the Latin word for ‘cake’ which is derived from the greek 
for a flat round surface (plakóeis/plakoús – πλακόεις, πλακούς) (Lidell et al. 1940).                             
After fertilisation, the zygote (fertilised ovum) divides. Once it reaches 32 cells in size, it is 
termed a ‘morula’ as it resembles a mulberry. The morula consists of early foetal cells 
called blastomeres in a solid ball contained within the zona pellucida (outer glycoprotein 
membrane of an ovum). Within a few days of formation, cells on the outer aspect of the 
morula bind tightly together in a process known as ‘compaction’. These cells secrete a 
viscous liquid such that a central cavity (known as a ‘blastocoele’) is formed in a process 
known as ‘hatching’ and the entire structure is termed a ‘blastocyst’.  A blastocyst 
comprises of 70-100 cells and the hatching process occurs at day 5 after fertilisation. The 
outer cell layer of the blastomere forms the trophoblasts which develops into the placenta 
and other extra-embryonic tissues, whereas cells from the inner part of the blastomere form 
the ‘inner cell mass’ or ‘embryoblast’ which form the ‘embryo proper’. 
The placenta begins to form when the blastocyst implants in the maternal endometrium at 
day 7 post fertilisation. The outer part of the trophoblast layer forms the 
syncitiotrophoblasts (or syncytium), whilst the inner trophoblast layer becomes 
cytotrophoblasts. The syncytium forms a continuous layer covering the whole of the 
placenta and contributes to the barrier function between the foetus and mother. In 
preparation for implantation the maternal endometrium undergoes a process called 
‘decidualisation’, during which maternal spiral arteries become less convoluted and 
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increase in diameter such that maternal blood flow to the placenta is maximised. Although 
the foetal chorion is bathed in maternal blood to allow gaseous and nutrient exchange to 
occur, no fluid is exchanged. Development of the placental blood flow is complete by 12-
13 weeks of gestation. The placenta continues to grow throughout pregnancy and typically 
weighs 400-1000 g in the third trimester (Pardi et al. 2002). 
 
The Placenta as an endocrine organ: 
 
As a pregnancy advances, the relative number of trophoblasts increases and the secretory 
function of the placenta begins to supersede that of foeto-maternal exchange. As gestation 
progresses towards term, the number of cytotrophoblasts is reduced and the 
syncitiotrophoblast layer at the foeto-maternal interface becomes very thin. During 
implantation the embryo actively secretes human chorionic gonadotrophin hCG (hCG), 
which is readily detectable in the maternal blood from 8 days after ovulation. hCG has an 
important role in maintaining secretion of progesterone from the corpus luteum, which in 
turn sustains a decidualised endometrium. The decidua is the endometrium of pregnancy 
and secretes a number of steroids and peptides including cortisol, prolactin and insulin-like 
growth factor binding protein-1 which help protect the foetus from the maternal immune 
system. The placenta is the main source of progesterone during pregnancy, which in 
addition to an important role in decidualisation of the placenta, also inhibits smooth muscle 
contractility, reduces prostaglandin production and contributes to the limitation of maternal 
immune responses (Feldt-Rasmussen et al. 2011)  (see table 6).  
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Table 6: Substances produced by the Placenta during Pregnancy.  
 
During pregnancy a number of substances and hormones are produced by the placenta and 
some of these are found at greatly increased circulating levels than those seen outside of 
pregnancy (adapted from Feldt-Rasmussen et al. 2011 and Kaitu'u-Lino et al. 2012). 
 
Substances found at increased circulating levels in pregnancy 
Human Chorionic Gonadotrophin (HCG) 
Oestrogen 
Progesterone 
Sex Hormone Binding Globulin (SHBG) 
Corticotrophic releasing hormone (CRH) 
Adrenocorticotrophic hormone (ACTH) 
Growth Hormone (GH) 
Parathyroid Hormone related peptide (PTHrp) 
Prolactin 
Human Placental Lactogen (HPL) 
Vascular Endothelial Growth Factor A (VEGF A) 
Other Angiogenic Factors : Placental Growth Factor (PlGF) and Angiopoietins 
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Prokineticins during Pregnancy: 
 
In 2001, Li et al. isolated and two peptides which potently stimulate rodent gastrointestinal 
tract smooth muscle and named them prokineticins (Li et al. 2001). In the same year, 
LeCouter et al. identified a new peptide, highly expressed in human testis, adrenal gland, 
ovary, and placenta which appeared to be a specific growth factor for endocrine gland-
derived endothelial cells (EC) (LeCouter et al. 2001). This protein was therefore termed 
endocrine gland derived vascular endothelial growth factor (EG-VEGF) to reflect its 
similarities to vascular endothelial growth factor (VEGF). However, EG-VEGF shared no 
sequence homology to VEGF and was instead found to be identical to PK-1 (LeCouter et 
al. 2001). For the remainder of this thesis I will use the term PK-1 (rather than EG-VEGF) 
for clarity. 
In endothelial cells (ECs) isolated from steroidogenic tissues such as the placenta, PK-1 
was shown to promote proliferation, survival, and chemotaxis. PK-1, but not Bv8/PK2, was 
found to be expressed in human placenta. PK-1 and its receptor PROKR1 are highly 
expressed in human placenta and are present in the syncytiotrophoblasts (ST), 
cytotrophoblasts (CT), fetal endothelium, and Hofbauer cells (Ho) (oval eosinophilic 
histiocytes found in the placenta) (see Figure 16) (Brouillet et al. 2012).  
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Figure 16: A diagragm of chorionic villi showing localisation for PK-1 (EG-VEGF) 
and its receptors, PROKR1 and PROKR2.  
 
 
EG-VEGF (PK-1) is mainly expressed by the syncytiotrophoblast (ST). PROKR1 is 
expressed by the cytotrophoblast (CT) and PROKR2 by the syncytiotrophoblast (ST), 
extravillous trophoblast (EVT) and endothelial cells. Abbreviations: DC, decidual cells; 
FBV, fetal blood vessel; Ho, Hofbauer cells; MBV, maternal blood vessel; Plug, aggregates 
of proliferative trophoblasts (Brouillet et al. 2012). 
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PK-1 is mainly localised to the syncytiotrophoblast layer of the placenta with the highest 
expression identified during 8-10th week of gestation (Hoffmann et al. 2006). Between 7–8 
weeks of gestation PK-1 expression is restricted to the syncytiotrophoblast layer, the 
endocrine unit of the placental villi and the Hofbauer cells. However, at more advanced 
gestational stages (9-12
th
 week of gestation), PK-1 expression is strongest in the 
syncytiotrophoblast and Hofbauer cells, with only mild expression in the cytotrophoblast 
layer (Hoffmann et al. 2006). Placental PK-1 expression peaks at 8–11th week of gestation, 
before gradually decreasing by the end of the first trimester (Hoffmann et al. 2006). This 
change in expression with gestation was also found to be reflected by serum levels of PK-1 
during pregnancy (see Table 7). Serum PK-1 levels are elevated during pregnancy, and are 
highest during the first trimester which is thought to be the critical period during which 
placentogenesis is thought to be established (Hoffmann et al. 2009).   
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Table 7: Circulating PK-1 levels during pregnancy 
Mean serum PK-1 levels (pg/ml) in non-pregnant and healthy pregnant women throughout 
gestation, and in pre-eclamptic women during the second and third trimester (n=9/group in 
non-pregnant, first trimester and second trimester; n=15-20 per group in third trimester 
pregnancy) (adapted from Brouillet et al. 2012 based on data from Hoffman et al. 2009). 
 
 
Normal women 
Non-pregnant women            35 ± 7 
First trimester of pregnancy 225 ± 39 
Second trimester of pregnancy 73 ± 11 
Third trimester of pregnancy 77 ± 5 
 
Pre-eclamptic women 
Second trimester of pregnancy  99 ± 10 
Third trimester of pregnancy 120 ± 13 
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The placenta is one of the most densely vascularized organs in humans. During the first 
trimester, the placenta invades into the maternal decidua (endometrium of pregnancy) and 
this process involves vascular remodelling, which peaks by the end of the first trimester 
before declining rapidly thereafter (Aplin 1991). At 10–12 weeks of gestation, 
cytotrophoblasts in the anchoring villi generate multi-layered columns of extravillous 
trophoblasts which colonise the interstitium of the maternal decidua, the inner third of the 
myometrium and the uterine blood vessels (Aplin 1991). The depth of invasion by placental 
trophoblasts into the maternal decidua is finely controlled. A defect in this process is 
thought to result in disordered placentogenesis and an increase in the risk of pregnancy 
complications (Hoffman et al. 2009). Shallow invasion of the maternal decidua 
(endometrium of pregnancy) by placental extravillous trophoblasts is thought to predispose 
to pre-eclampsia and intra-uterine growth restriction (IUGR); whereas excessive invasion to 
choriocarinoma, placenta accreta (abnormally deep attachment of the placenta to the 
myometrium) and invasive mole (Hoffman et al. 2009; Brouillet et al. 2012).  PK-1 has an 
inhibitory effect on placental invasion as supported by a decrease in matrix 
metalloproteinases 2 and 9 (MMP-2 and MMP-9) production (Hoffman et al. 2009). 
Furthermore, interference with PKR2 expression using specific siRNAs, reverses the PK-1-
induced inhibition (Hoffman et al. 2009). The involvement of PK-1 in human placental 
angiogenesis has been demonstrated by data looking at the placental microvascular 
endothelial cells (HPEC) which cover foetal capillaries in the chorionic villi, ensure foeto-
maternal exchanges and provide a framework for placental angiogenesis (Brouillet et al. 
2012). These data demonstrate that PK-1 stimulates a number of angiogenic processes 
including endothelial proliferation, survival, migration, tube organization, sprouting, 
permeability, and paracellular transport (Brouillet et al. 2010). Furthermore, PK-1 has a 
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stronger effect on placental microvascular endothelial cell sprouting and permeability than 
the more established angiogenic factor VEGF (Brouillet et al. 2010).  
The expression of PK-1 and its receptor have been shown to be up-regulated by hypoxia 
(Hoffmann et al. 2006). Early embryonic development occurs under a hypoxic environment 
(∼20 mm Hg or 3% O2), which protects developing organs from the harmful effects of 
radical oxygen species, as embryonic tissues express low levels of antioxidant enzymes 
during early pregnancy (Brouillet et al. 2012). The hypoxic environment in the decidua 
lasts throughout the first trimester. Thus, the peak in PK-1 and PKR-1 expression observed 
at 8–11 weeks of gestation cannot be explained solely by regulation by hypoxia. Other 
regulators of placental PK-1 expression may include hCG, which has similar temporal 
expression to PK-1 (peak hCG levels occur at 8-9 weeks of gestation). Exposure to hCG 
has been shown to induce a five-fold increased secretion of PK-1 from placentas collected 
at 6-8 weeks of gestation, but only 1.5 fold from placentas collected at 9-11 weeks 
(Hoffmann et al. 2006).   
Furthermore, PK-1 expression in the endometrium peaks during the mid-luteal window of 
embryonic implantation and PK-1 has been identified as a marker of human endometrial 
receptivity (Brouillet et al. 2012). PK-1 directly regulates implantation related genes and 
increases human trophoblast cell adhesion to extracellular matrix proteins via the induction 
of leukaemia inhibitory factor (LIF) (Evans et al. 2009). 
To summarise PK-1 plays an important role in placental angiogenesis, especially during the 
first trimester. Lower levels of PK-1 may therefore be seen in disordered placental 
invasion, and may predispose to pregnancy complications such as miscarriage.  
 
 
 
 97 
Other novel markers of pregnancy complications: Kisspeptin 
 
 
Invasion of foetal trophoblasts into the maternal endometrium is a process, which can be 
regarded as analogous to the metastatic invasion of tumour cells into surrounding tissues. 
Kisspeptin is a hormone, which was first discovered in 1996 as a peptide with anti-
metastatic properties and was termed ‘metastin’. Kisspeptin is highly expressed in the 
placenta and circulating levels of kisspeptin are markedly elevated during pregnancy 
(Horikoshi et al. 2004). Kisspeptin has been proposed to play an important role in the 
invasion of foetal trophoblasts into the maternal endometrium. Circulating plasma 
kisspeptin levels may provide a marker of placental function and are a strong candidate for 
investigation as a novel predictive marker of miscarriage in pregnancy.    
The kisspeptins are a family of RF amide peptides with arginine–phenylalanine residues 
present at the amino terminal. The 145 amino acid gene product from the KiSS1 gene is 
cleaved into kisspeptin isoforms of different sizes (kisspeptin-54, kisspeptin-10, kisspeptin-
13, kisspeptin-14) with the suffix denoting the number of amino acids (see Figure 17). All 
kisspeptin isoforms have a C-terminal decapeptide moiety, which is critical for their 
biological action. Kisspeptin mRNA is peripherally expressed in the testis, ovary, pancreas 
and small intestine, however highest levels of kisspeptin expression are found in the 
placenta (Ohtaki et al. 2001). Exogenous administration of kisspeptin stimulates 
gonadotrophin releasing hormone (GnRH) release and subsequently gonadotrophin release. 
Sustained exposure to continuous administration of kisspeptin results in desensitisation to 
its effects in some species, including humans. This is thought to be mediated at the level of 
the kisspeptin receptor as response to GnRH is maintained. Circulating kisspeptin levels are 
elevated 7,000-fold during pregnancy and it has been postulated that the hypothalamo-
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pituitary axis may be desensitised to effects of kisspeptin as a result of this prolonged high 
level exposure. However exogenous administration of kisspeptin-10 to pregnant rodents is 
still able to stimulate the hypothalamo-pituitary axis (Hameed et al. 2010).  
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Figure 17:  Kisspeptin isoforms  
 
The 145 amino acid peptide product of the KiSS1 gene is cleaved into kisspeptin isoforms 
of length denoted by their suffix e.g. kisspeptin-54 (Kp-54), kisspeptin-10 (Kp-10), 
Kisspeptin-14 (Kp14), and Kisspeptin-10 (Kp-10). The C-terminal decapeptide sequence is 
critical for the biological action of the kisspeptins. Kisspeptin-54 is the major circulating 
isoform during pregnancy (adapted from Bilban et al. 2004). 
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Kisspeptin as an anti-metastatic marker 
 
Kisspeptin-54 has anti-metastatic properties in malignant melanoma cells and was hence 
initially termed ‘metastin’ (Lee et al 1996). Melanoma cells transfected with kisspeptin 
receptors have reduced growth and invasiveness in vitro (Ohtaki et al. 2001). Kisspeptin-10 
and activation of the kisspeptin receptor have been shown to negatively regulate the 
chemotactic activity of another G-protein coupled receptor, the chemokine receptor 4 
(CXCR4 receptor), which has a role in promoting metastasis. Kisspeptin is thought to play 
a role in a number of malignancies including breast, melanoma, gastric, hepatocellular, 
endometrial, and gestational trophoblastic disease (Makri et al. 2008). Kisspeptin 
negatively regulates matrix metalloproteinases (MMPs) in ovarian and hepatocellular 
carcinoma. These enzymes degrade the extracellular matrix and play an essential role in 
tumour cell invasion. Importantly MMPs also inactivate kisspeptins and the balance 
between kisspeptin and MMP activity may be an important factor in determining cancer 
cell invasion. Kisspeptin-54 treatment in thyroid cancer cells increases the calcineurin 
inhibitor Myocyte-enriched Calcineurin Interacting Protein 1 (MCIP1). MCIP1 inhibits 
VEGF induced cell motility and angiogenesis in vascular endothelial cells (Makri et al. 
2008).  
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Kisspeptin in the placenta 
 
The invasion into and proliferation of trophoblasts in the maternal endometrium is often 
considered analogous to an invasive neoplastic process. However importantly and in 
contrast to a neoplastic process, the invasion of trophoblasts is highly regulated and 
kisspeptin has been proposed as a putative regulator of trophoblastic invasion. 
Choriocarcinoma cells have reduced kisspeptin receptor mRNA expression in keeping with 
kisspeptin’s role as a metastasis suppressor gene (Janneau et al. 2002).  
Bilban et al. 2004 localised kisspeptin mRNA expression and kisspeptin peptide to the 
syncitiotrophoblasts of anchoring and floating villi. Kisspeptin peptide distribution was 
undetectable in the maternal decidua and in villous/extra-villous cytotrophoblasts (Bilban et 
al. 2004).  Hence kisspeptin expression appears to correlate with trophoblastic cells which 
have fused and are no longer invasive, whereas cytotrophoblasts only express the kisspeptin 
receptor. Therefore kisspeptin production by syncitiotrophoblasts may have an important 
paracrine role in regulating cytotrophoblastic invasiveness (Bilban et al. 2004).  
Furthermore incubation with kisspeptin-10 (but not other isoforms of kisspeptin) lowers in 
vitro trophoblast migration by 70%, without affecting cytotrophoblast proliferation (Bilban 
et al. 2004).  
Angiogenesis is a complex process involving multiple steps such as endothelial cell 
proliferation, migration, and tube formation. Kisspeptin has been shown to have 
vasoconstrictor properties in vitro. Both kisspeptin and its receptor are found in the 
endothelial and smooth muscle cells of human umbilical vein, placental blood vessels, 
aorta, and coronary arteries. Incubation of placental artery explants with kisspeptin-10 in 
vitro inhibited new vessel sprouting and tube-like structure formation by human umbilical 
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vein endothelial cells (HUVEC) in a concentration dependent manner. Although HUVEC 
cell viability was unaffected, cell proliferation and migration were reduced in a 
concentration dependent manner (Ramaesh et al. 2010).  
Kisspeptin-10 inhibits in vitro cell migration of a human placental cell line derived from 
first trimester extra-villous trophoblasts (Roseweir et al. 2012). Kisspeptin also inhibits 
chemokine receptor 4 (CXCR4) and metalloproteinase-9 (MMP-9) in vitro (Yan et al. 
2001). CXCR4 is believed to have an important role in the implantation of the blastocyst in 
the decidua and MMP 9 degrades the extracellular matrix making cell migration and 
invasion possible (Bilban et al. 2004).   
 
Kisspeptin expression in Recurrent Pregnancy Loss 
 
 
Park et al. 2012 collected trophoblastic and decidual tissues from women with at least 2 
miscarriages of a genetically normal foetus and women who had had an elective 
termination (controls). In controls, kisspeptin protein was most abundantly found in 
syncytiotrophoblasts. Kisspeptin peptide distribution was reduced in the 
syncitiotrophoblasts of women with recurrent miscarriage (Park et al. 2012).  
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Circulating levels of kisspeptin in pregnancy 
 
Horikoshi et al. 2004 were the first to assess circulating levels of kisspeptin in pregnancy. 
They used a sensitive and specific two-site enzyme immunoassay to investigate kisspeptin-
54 levels in human plasma (Horikoshi et al. 2004). Mean plasma concentrations of 
kisspeptin-54 in non-pregnant females was 1.31 pmol/l (n = 10). The plasma kisspeptin-54 
level was 1230 pmol/l (n = 11) in the 1st trimester, 4590 pmol/l (n = 16) in the 2nd 
trimester, and 9590 pmol/l (n = 12) in the 3rd trimester of pregnancy. Five days after 
delivery, kisspeptin-54 levels returned almost to the non-pregnant levels (7.63 pmol/l) 
suggesting that kisspeptin is predominantly derived from the placenta (Horikoshi et al. 
2004) (see Figure 18). Kisspeptin is therefore secreted by the placenta into the circulation at 
high levels, making it an ideal candidate biomarker for detecting complications of 
pregnancy.  
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Figure 18: Kisspeptin-54 levels are raised during normal human pregnancy 
Serum Kisspeptin-54 was measured in the first, second and third trimesters and was found 
to be raised several thousand fold those found in non-pregnant women (adapted from 
Horikoshi et al. 2004).  
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Circulating kisspeptin levels and Threatened Miscarriage 
 
 
Kavvasoglu et al. 2012 measured kisspeptin levels in 20 pregnant women with threatened 
miscarriage (PV bleeding) and 20 healthy controls matched for gestation. Kisspeptin levels 
were found to be significantly lower in the study group compared to the control group (391 
vs. 5783 pg/mL; P <0.01). Birth weight was lower in the study group than that of the 
control group (2100g vs. 2860g, p = 0.06). A greater percentage of the study group required 
caesarean section or curettage (75%) as compared with the control group (45%, P=0.04) 
(Kavvasoglu et al. 2012). 
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Other angiogenic markers of pregnancy complications:  
 
 
Maternal blood flow to the placental inter-villous space becomes established towards the 
end of the first trimester. Between 11 and 12 weeks the trophoblast plugs dislodge and there 
is sudden perfusion of the placental inter-villous space. Prior to this, the development of the 
human embryo takes place in a relatively hypoxic environment. It has been proposed that 
hypoxia plays an important role in protecting dividing foetal and placental cells from 
exposure to free radicals during the critical early pregnancy growth period (Kaitu'u-Lino et 
al. 2012). 
Soluble fms-like tyrosine kinase-1 (sFlt1) is an endogenous anti-angiogenic protein that is 
made by the placenta and acts to neutralize pro-angiogenic proteins including vascular 
endothelial growth factor (VEGF) and placental growth factor (PlGF). Free VEGF is 
undetectable in maternal serum, which may be due to it being bound by sFlt1. sFlt1 binds 
to PLGF and therefore high circulating sFlt1 has been associated with lower circulating 
PLGF. sFlt1 and soluble endoglin (sEng) (a glycoprotein which is part of the TGF-beta1 
receptor complex) are up-regulated by placental hypoxia. sFlt1 is up-regulated by 
cytotrophoblasts in hypoxia, whilst placental growth factor (PLGF) is the most abundantly 
regulated angiogenic factor in uncomplicated first trimester decidua. PLGF is 
predominantly expressed in the syncytiotrophoblast, and is secreted directly into the 
maternal circulation in a similar manner to kisspeptin. Circulating PLGF levels increase as 
placental mass increases (Kaitu'u-Lino et al. 2012). 
Recently Kaitu'u-Lino et al. 2012 measured soluble FMS-like tyrosine kinase-1 (sFlt1), 
placental growth factor (PLGF), and soluble endoglin (sEng) in the serum of an 
asymptomatic cohort of pregnant women in the first trimester of pregnancy. Whilst serum 
levels of sFlt1 and PLGF rose with increasing gestation, serum endoglin levels remained 
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stable throughout the first trimester.  Women who went on to miscarry had significantly 
reduced maternal sFlt-1 (decreased by 35%, P <0.05), but not PLGF or sEng when 
compared with women with healthy pregnancies. However due to over-lap in levels 
between women who miscarried and those who did not, serum Flt-1 cannot be used in 
isolation to predict miscarriage (Kaitu'u-Lino et al. 2012). 
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Hypothesis and aims 
 
 
Hypothesis 
 
PK-1 (also known as endocrine-gland vascular endothelial growth factor) is an angiogenic 
peptide, which plays an important role in the vascular invasion of the placenta into the 
maternal endometrium. Abnormal placentation may occur as a result of abnormal 
angiogenesis. Alterations in plasma PK-1 levels may thus correlate with the risk of 
pregnancy related complications such as miscarriage.   
 
 
 
 
Aims 
1. Characterise the levels of PK-1 in the plasma of pregnant women and correlate the 
levels of PK-1 with the occurrence of pregnancy related complications.  
2. Characterise the levels of other novel markers of pregnancy complications such as 
kisspeptin (KP), soluble FMS-like tyrosine kinase-1 (FLT-1), placental growth 
factor (PLGF), and soluble endoglin (ENG) in the same cohort.  
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Material and methods 
 
 
Ethical approval was granted by the Hammersmith and Queen Charlotte’s and Chelsea 
Hospitals Research Ethics Committee (registration number: Q0406/80). This study was 
performed in accordance with the Declaration of Helsinki. Written informed consent was 
obtained from all participants. In order to reduce selection bias, all women attending 
routine antenatal booking visit at this centre (between 1 January 2010 and 31 December 
2012) were approached and invited to participate in the study. Women with renal failure 
were excluded due to possible interference with kisspeptin measurement. Women attending 
clinic as an emergency or with suspected miscarriage were excluded. Nine hundred and 
ninety-three pregnant women attending their routine antenatal booking clinic appointment 
at Queen Charlotte’s and Chelsea Hospital (a tertiary obstetric centre), London, UK, were 
recruited. Twelve women were lost to follow-up, and staff at the obstetric centre attempted 
to contact these women. The remaining 981 women were followed-up until the outcome of 
pregnancy was known (see Figure 19). 
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Figure 19: Protocol for Study.  
 
Asymptomatic pregnant women were recruited in early pregnancy and blood was sampled 
for measurement of plasma prokineticin 1 (PK1), kisspeptin (KP), serum BHCG (BHCG), 
serum endoglin (ENG), serum FLT-1 (FLT-1) and placental growth factor (PLGF).  
Women were then prospectively followed up for assessment for pregnancy outcomes.  
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Methods 
 
I collected blood samples from pregnant women (n=981) attending Queen Charlotte and 
Chelsea hospital outpatient antenatal clinic. As part of standard NHS care for pregnant 
women a routine booking visit is scheduled to occur between 8-10 weeks and involves an 
assessment of BMI, blood pressure and an evaluation by a midwife to identify women at 
risk of complications. At booking, a blood test is taken for blood group determination, 
previous infections with importance in pregnancy such as rubella and HIV, iron status, 
routine full blood count and renal and liver function measurement. Women return at ~12 
weeks for an ultrasound scan which is used to date the pregnancy and assess the nuchal 
thickness (NT). The NT is combined with a blood test to identify women at higher risk of 
trisomy 21, who may then opt for a chorionic villus sampling (CVS) (or amniocentesis if 
later in the pregnancy) to confirm a genetic diagnosis if found to be at high risk. Women 
next visit at 20 weeks for an anomaly scan to assess for normal foetal development and the 
risk of a low lying placenta. Thereafter no routine scans are undertaken unless there are 
concerns regarding foetal growth, placental position or there is multiple pregnancy. One 
further routine blood test occurs at 28 weeks and women may have a further blood test prior 
to a caesarean section.  
I also obtained blood samples from non-pregnant women (n=50) attending outpatient 
phlebotomy at Hammersmith Hospital. Written consent was obtained from all participants 
in the study. Participants were asked details such as name, date of birth, hospital number, 
gestation, parity, previous history of miscarriages and medical history.   
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Dating of pregnancy   
 
Gestational age is historically derived from knowledge of last menstrual period (LMP), 
however in approximately 40% of cases, this is either not known or inaccurate (Verburg et 
al. 2008). Ultrasound dating of pregnancy is usually calculated based on crown–rump 
length (CRL) or biparietal diameter (BPD). Median gestational age can be calculated using 
Crown–rump length = exp(1.4653 + 0.001737 × CRL + 0.2313 × log (CRL)). For example 
a CRL of 5mm corresponds to a gestational age of 6+2 and 40mm to 10+1 (Verburg et al. 
2008). In the absence of serious pathology such as foetal chromosomal abnormality, or 
severe maternal malnutrition, foetal growth in early pregnancy is fairly uniform. Therefore 
ultrasound is more accurate than using LMP at deriving gestational age particularly in early 
pregnancy (<20 weeks gestation) (Verburg et al. 2008). Hence I have used gestational ages 
derived from ultrasounds carried out at 10-14 weeks where possible to calculate gestational 
age at time of sampling. Women were classified as first trimester from 0-14 weeks, second 
trimester from 14-28 weeks and third trimester if >28 weeks.   
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Measurement of circulating markers of pregnancy complications levels 
 
Collection and processing of blood samples 
 
All patients donated 5mls of blood in a serum clot activator tube and 5mls in a lithium 
heparin tube (Beckton Dickson, Franklin Lakes, NJ, USA) with 2000 units/tube containing 
5,000 kallikrein units of aprotinin (0.2 ml; trasylol, Bayer, Newbury, UK). The lithium 
heparin tube with 2000 units/tube of trasylol was used for measurement of plasma levels 
(kisspeptin and PK-1). Lithium heparin tube with 2000 units/tube of trasylol samples were 
immediately spun following collection at 6,400 x g for 4 minutes and plasma supernatant 
was aliquoted into eppendorf tubes. Plasma samples were then immediately placed in dry 
ice until transfer to a -20
o
C freezer. Serum samples collected in a serum clot activator tube 
were allowed to sit at room temperature until a clot had formed (at least 1 hour) and then 
spun at 4,800 x g for 10 minutes. Serum supernatant was separated and stored at -20
o
C for 
measurement of BHCG, PLGF, FLT-1 and ENG. All samples were analysed together in 
order to minimise assay variation. 
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Measurement of PK-1 immuno-reactivity 
Plasma PK-1 was measured using a commercially available ELISA kit (ABNOVA) as  
described in Chapter 2.  
 
 
Measurement of total Kisspeptin immuno-reactivity 
 
Plasma kisspeptin immuno-reactivity (kisspeptin IR) was measured using a manual 
radioimmunoassay. Antibody GQ2 was raised in sheep immunised with synthetic human 
kisspeptin-54 (Bachem UK Ltd.) conjugated to bovine serum albumin (BSA) by 
glutaraldehyde and used at a final dilution of 1:3,500,000. The antibody cross-reacted 
100% with human kisspeptin-54, kisspeptin-14, and kisspeptin-10 and less than 0.01% with 
other related RF amide proteins, including prolactin-releasing peptide, RF amide-related 
peptide 1 (RFRP1, human and rat), RFRP2 (human), RFRP3 (human), QRFP43 (human), 
neuropeptide FF (human), and neuropeptide AF (human). The iodogen method was used to 
prepare the 125I-kisspeptin-54 label, which was subsequently purified by High 
Performance Liquid Chromatography (Salacinski et al 1981). The assay was carried out in 
duplicate using dilutions of neat plasma in 0.7ml of 0.06M phosphate buffer (pH 7.2) 
containing 0.3% BSA. Incubation was for 3 days at 4
o
C. Subsequently free and antibody-
bound label were separated by charcoal adsorption. The limit of detectability was 2 pmol/l 
of plasma kisspeptin with 95% confidence interval, and the intra- and inter-assay 
coefficients of variation were 8.3 and 10.2%, respectively (Ramachandaran et al. 2008, 
Dhillo et al. 2005). 
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Measurement of Total hCG immunoreactivity 
 
Measurement of plasma hCG was performed using the Siemens Immulite 2000 total 
immunometric hCG assay run on board the Siemens Immulite 2000 instrument (Siemens 
Healthcare Diagnostics 1717 Deerfield Road, Deerfield, IL, USA). According to the 
manufacturer’s kit insert the analytical sensitivity of the assay is 0.4 IU/L. Performance is 
monitored daily and internal quality control samples ranging 5-250 IU/L yield intra- and 
interassay coefficients of variation (CV) of less than 10%. Studies using the latest WHO 
standard preparations for common hCG protein variants have demonstrated that the 
Immulite 2000 assay detects all hCG isoforms, but is associated with relative slight 
overestimation of hCGβ and under-detection of the hCGβ core fragment isoforms 
(Sturgeon et al. 2009; Harvey et al. 2010). 
 
Measurment of PLGF by ELISA (RnDsystems, Minneapolis, USA) 
 
The PLGF Standard was reconstitured with 1 mL of Calibrator Diluent. This reconstitution 
produces a stock solution of 1000 pg/mL. The standard is allowed to sit for a minimum of 
15 minutes with gentle agitation prior to making dilutions. 500 μL of the Calibrator Diluent 
is then pipetted into each tube. The undiluted standard serves as the high standard (1000 
pg/mL). The stock solution to produce a dilution series to generate standards of 500 pg/ml, 
250 pg/ml, 125 pg/ml, 62.5 pg/ml, 31.2 pg/ml and 15.6 pg/ml. 100 μL of Assay Diluent 
RD1-22 is added to each well. 100 μL of Standard, control, or sample is added to each well. 
The plate is covered with an adhesive strip. The plate is incubated for 2 hours at room 
temperature. Each well is aspirated and washed with 400 µls wash buffer for 4 cycles. 200 
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μL of PLGF Conjugate is added to each well and incubated for 2 hours. Each well is again 
aspirated and washed with 400 µls wash buffer for 4 cycles. 200 μL of Substrate Solution is 
added to each well and incubated for 30 minutes at room temperature in the dark. 50 μL of 
Stop Solution is added to each well. The optical density of each well is determined within 
30 minutes, using a microplate reader set to 450 nm with wavelength correction set to 570 
nm.  
 
Measurment of Endoglin by ELISA (RnDsystems, Minneapolis, USA) 
 
The Endoglin Standard was reconstitured with 1 mL of Calibrator Diluent. This 
reconstitution produces a stock solution of 100 ng/mL. The standard is allowed to sit for a 
minimum of 15 minutes with gentle agitation prior to making dilutions. 100 μL of the 
standard solution is pipetted into 900 μL of Calibrator Diluent to generate a concentration 
of 10 ng/ml. Then 500 μL of the Calibrator Diluent is then pipetted into each tube. The 
stock solution to produce a dilution series to generate standards of 5 ng/ml, 2.5 ng/ml, 1.25 
ng/ml, 0.625 ng/ml, 0.313 ng/ml and 0.156 ng/ml. 100 μL of Assay Diluent RD1S is added 
to each well. 100 μL of Standard, control, or sample is added to each well. The plate is 
covered with an adhesive strip. The plate is incubated for 2 hours at room temperature. 
Each well is aspirated and washed with 400 µls wash buffer for 4 cycles. 200 μL of 
Endoglin Conjugate is added to each well and incubated for 2 hours. Each well is again 
aspirated and washed with 400 µls wash buffer for 4 cycles. 200 μL of Substrate Solution is 
added to each well and incubated for 30 minutes at room temperature in the dark. 50 μL of 
Stop Solution is added to each well. The optical density of each well is determined within 
30 minutes, using a microplate reader set to 450 nm with wavelength correction set to 570 
nm.  
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Measurement of FLT-1 by ELISA (RnDsystems, Minneapolis, USA) 
 
High concentrations of FLT-1 is found in saliva and therefore a face mask and gloves to 
protect kit reagents from contamination was employed throughout. The FLT-1 Standard 
was reconstitured with 1 mL of deionised water to produces a stock solution of 20,000 
pg/mL. The standard is allowed to sit for a minimum of 15 minutes with gentle agitation 
prior to making dilutions. 100 μL of the standard solution is pipetted into 900 μL of 
Calibrator Diluent to generate a concentration of 2000 pg/ml. Then 500 μL of the 
Calibrator Diluent is then pipetted into each tube. The stock solution to produce a dilution 
series to generate standards of 1000 pg/ml, 500 pg/ml, 250 pg/ml, 125 pg/ml, 62.5 pg/ml 
and 31.2 pg/ml. 100 μL of Assay Diluent RD6-68 is added to each well. 100 μL of 
Standard, control, or sample is added to each well. The plate is covered with an adhesive 
strip. The plate is incubated for 2 hours at room temperature. Each well is aspirated and 
washed with 400 µls wash buffer for 4 cycles. 200 μL of FLT-1 Conjugate is added to each 
well and incubated for 2 hours. Each well is again aspirated and washed with 400 µls wash 
buffer for 4 cycles. 200 μL of Substrate Solution is added to each well and incubated for 30 
minutes at room temperature in the dark. 50 μL of Stop Solution is added to each well. The 
optical density of each well is determined within 30 minutes, using a microplate reader set 
to 450 nm with wavelength correction set to 570 nm.  
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Data Analysis and Statistics 
 
Data was analysed using Prism version 5 (GraphPad, California). In order to account for 
variation in circulating blood markers with gestation, I calculated multiples of median 
(MoM) levels of each hormone measurement correcting for the gestation at which the blood 
was collected. Pairs of means were analysed using the unpaired two-tailed t-test. Multiple 
means were compared using one-way ANOVA with post hoc bonferroni or Dunnet’s 
Multiple Comparison Test. In all cases, P < 0.05 was considered statistically significant. 
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Patient details and outcomes:  
 
All pregnancies were dated according to a dating ultrasound scan (typically at 8-14weeks 
gestation) routinely performed in the antenatal clinic. Ultrasound parameters from a 20-
week fetal anomaly scan, patient-held clinical notes, and hospital electronic database 
records were collated for study participants to establish whether miscarriage or live birth 
had occurred. Miscarriage was either diagnosed using ultrasound scanning, or was self-
reported by the patient. Patient clinical details are summarised in Table 8. 
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Baseline characteristics of pregnant subjects attending their antenatal booking visit 
 
Nine hundred and ninety-three women attending antenatal clinic for a routine booking 
antenatal appointment were recruited to the study. Twelve women (1% of the sample) were 
lost to follow-up (therefore the outcome of their pregnancies could not be determined) and 
their data was excluded from all analyses (see Figure 20). The remaining 981 women had a 
mean gestation of 11.2 weeks (range 5.9-29.0), mean age 32.6 years old (see Table 8). 
There was no missing data for each variable of interest for each of the 981 women included 
in the analyses. 50 of these women had singleton pregnancy which subsequently resulted in 
miscarriage. These parameters were similar between women with healthy pregnancies 
which did not result in miscarriage and women whose pregnancies subsequently resulted in 
miscarriage. Thirty-two of the pregnancies were multiple: 30 twin pregnancies (6 
monochorionic and 24 dichorionic) and 2 triplet pregnancies. No participants attended 
clinic as an emergency, or presented with any symptoms of threatened miscarriage such as 
abdominal pain or vaginal bleeding at the time of recruitment.  
Participants with singleton pregnancy were also classified by gestational week of 
pregnancy at time of recruitment. The majority of singleton pregnancies subsequently 
resulting in miscarriage (47/50) were recruited prior to the 12th gestational week of 
pregnancy. Most singleton pregnancies not resulting in miscarriage (554/899) were also 
recruited prior to the 12th gestational week of pregnancy. Thus this study provided a large 
pool of gestation-matched non-cases with which to compare levels of blood markers with 
miscarriage cases. 
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Figure 20: Flowchart of pregnant women recruited to the study and main outcomes 
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Table 8: Clinical characteristics of study participants 
 
 
 
 N number Mean 
Age 
(years) 
(±s.d.) 
Mean 
BMI 
(kg/m
2
) 
(±s.d.) 
Mean 
Parity 
 
(±s.d.) 
Mean 
Gestation 
(weeks) 
(±s.d.) 
Total number of women participating in 
study 
981 
32.6 
(±2.0) 
24.8 
(±5.5) 
0.6 
(±0.8) 
11.2 
(±2.0) 
Number of women with  
singleton pregnancy without miscarriage 
899 
32.4 
(±5.1) 
24.7 
(±5.4) 
0.7 
(±0.8) 
11.3 
(±1.9) 
Number of women  
with singleton miscarriage 
50 
33.1 
(±4.8) 
26.3 
(±7.4) 
0.6 
(±0.8) 
9.8 
(±3.1) 
Number of women with multiple pregnancy 32 35.5 25.9 0.5 10.7 
  (±5.6) (±5.6) (±0.9) (±1.5) 
Ethnicity (981) Caucasian 574 (58.5%) 
 South Asian 121 (12.3%) 
 Afrocaribbean 107 (10.9%) 
 Other 109 (11.1%) 
 Mixed 24 (2.4%) 
 Unknown 46 (4.7%) 
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Results:  
Levels of plasma Prokineticin-1 (PK-1) in non-pregnant women 
Plasma PK-1 levels in 50 non-pregnant women aged between 18 and 74 years old.  
The majority of women had levels less than 200 pg/ml. The median plasma PK-1 level in 
non-pregnant women was 55 pg/ml with an interquartile range of 8.3 to 162 pg/ml. It is not 
clear why a small number of women had high detectable levels of PK-1 in the plasma 
(some above the reference range of the assay) and there was no clear correlation with age 
(r
2 
is only 0.05) (see Figure 21). It is possible that an as of yet unidentified factor results in 
raised plasma PK-1 in some individuals.  
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Figure 21: Levels of plasma PK-1 in non-pregnant women.  
Plasma Prokineticin-1 (PK-1) levels in 50 non-pregnant women aged between 18 and 74 
years old. There was no clear correlation with age (r
2 
only 0.05).  
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Correlation of Prokineticin-1 (PK-1) with serum BHCG levels 
 
It was previously suggested that as PK-1 is thought to show a similar temporal pattern of 
secretion to BHCG, that BHCG was a regulator of PK-1 secretion.  
Therefore I analysed whether PK-1 levels correlated with serum BHCG levels.  
However there was no significant correlation in this larger data set with r
2
 only 0.0034 and 
P=0.084 (see Figure 22).   
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Figure 22: Correlation of Prokineticin-1 (PK-1) with serum BHCG levels 
Linear correlation between plasma PK-1 levels and serum BHCG in women with singleton 
pregnancy uncomplicated by miscarriage. There is no significant correlation r
2
 is only 
0.0034 and P=0.084.  
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with gestation:  
 
Levels of PK1 did not show a clear relationship with gestational week in singleton 
pregnancies uncomplicated by miscarriage (see Figure 23).  
Levels of plasma kisspeptin in singleton pregnancies increased steadily during each week 
of gestation during the first trimester of pregnancy (Figure 23). Plasma kisspeptin levels 
were highly significantly and positively correlated with the gestational week of pregnancy 
(r
2
=0.32; P<0.0001) (Table 9). By comparison, levels of serum hCG in single pregnancies 
were highest during the 8th week of gestation, then decreased steadily with increasing 
gestation (Figure 23). Thereafter serum hCG levels were significantly and negatively 
correlated with the gestational week of pregnancy (r
2
=-0.18; P<0.0001) (Figure 23). Serum 
endoglin levels increase until 10 weeks of gestation before remaining steady thereafter at 
higher gestations. Serum FLT-1 levels only changed marginally with gestation. Serum 
placental growth factor levels increased significantly with gestation (r
2
=0.51; P<0.0001) 
and was highly correlated.  
In order to reduce the impact of gestation on further analyses, I calculated medians for each 
gestation and expressed blood markers as multiples of gestation specific median (MOM). 
This is important as miscarriage often occurs at earlier gestation and if gestation were not 
corrected for, blood levels of markers associated with miscarriage may be be lower than 
control group pregnancies purely due to the effect of gestation (see Table 10).  
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Figure 23: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with gestation. 
Mean and Standard error of mean of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF is shown for each week of gestation in women 
with singleton pregnancy which did not end in miscarriage (n=899). 
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Table 9: Correlation of levels of plasma Prokineticin-1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with gestation.  
Correlation of blood markers with gestation by linear regression in singleton pregnancy 
which did not result in miscarriage (n=899).  
 
 
 
 
 Plasma 
Prokineticin-1 
level 
(pg/ml) 
Plasma 
Kisspeptin 
(pmol/l) 
Serum 
BHCG 
(iU/L) 
Serum 
Endoglin 
(ng/ml) 
Serum 
FLT-1 
(pg/ml) 
Serum 
PLGF 
(pg/ml) 
 
R 
(slope of 
change 
with 
gestation) 
 
1.82 
± 5.66 
 
305.4 
± 14.80 
 
-8618 
± 620.6 
 
0.073 
±0.029 
 
-31.12 
±6.441 
 
13.26 
±0.4395 
 
 
 
R
2
 
(goodness 
of fit) 
0.00011 0.32 0.18 0.0069 0.026 0.51 
 
 
 
 
 
 
P Value 0.75 < 0.0001 < 0.0001 0.013 < 0.0001 < 0.0001 
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Table 10: Gestation of pregnancy during which study participants with singleton 
pregnancy were recruited to the study.  
Plasma kisspeptin was measured on the day of recruitment, and pregnancies were classified 
by the subsequent diagnosis of miscarriage. 
 
Gestation 
(weeks) 
Number of participants with 
singleton pregnancy not resulting 
in miscarriage (N=899) 
Number of participants with 
singleton pregnancy resulting in 
miscarriage (N=50) 
<8 12 (1.3%) 2 (4.0%) 
8-8.9 75 (8.3%) 15 (30.0%) 
9-9.9 164 (18.2%) 17 (32.0%) 
10-10.9 167 (18.6%) 7 (14.0%) 
11-11.9 136 (15.1%) 6 (12.0%) 
12-12.9 198 (22.0%) 3 (6.0%) 
13-13.9 91 (10.1%) 0 (0%) 
14-14.9 19 (2.1%) 0 (0%) 
≥15 37 (4.1%) 0 (0%) 
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with multiple pregnancy and miscarriage:  
 
Thirty-two of the subjects participating in the study had multiple pregnancy (twins or 
triplets). I therefore investigated the observed relationship between blood markers and 
multiple pregnancy. Some of the participants with twin pregnancy (n=10) were also 
affected by foetal loss of one of the twins. I therefore investigated whether these 
participants had changes in their levels of blood markers in comparison to participants with 
multiple pregnancy unaffected by miscarriage.  
Plasma levels of PK-1 did not show a clear relationship with multiple pregnancy, although 
appeared to be highest in twins affected by miscarriage (see Figure 24).  
Plasma kisspeptin showed a more consistent and predictable change with multiple 
pregnancy and miscarriage. MoM of plasma kisspeptin was higher in twin and triplet 
pregnancies unaffected by miscarriage when compared with singleton pregnancies 
unaffected by miscarriage (median of MoM plasma kisspeptin: 1.0, singleton no 
miscarriage (n=899); 1.31, monochorionic twin no miscarriage (n=3); 1.7, dichorionic twin 
no miscarriage (n=17); 2.1, triplet no miscarriage (n=2)). However plasma kisspeptin levels 
were reduced in women with twin pregnancy affected by miscarriage (median of MoM 
plasma kisspeptin: 0.23, singleton with miscarriage (n=50); 0.82, monochorionic twin with 
miscarriage (n=3); 1.17, dichorionic twin with miscarriage (n=7)). Levels of kisspeptin in 
women with twin pregnancy affected by miscarriage were similar to those found in healthy 
singleton pregnancy.  
MoM serum BHCG was higher in twin and triplet pregnancies unaffected by miscarriage 
when compared with singleton pregnancies unaffected by miscarriage (median of MoM 
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plasma kisspeptin: 0.99, singleton no miscarriage (n=899); 1.56, monochorionic twin no 
miscarriage (n=3); 1.52, dichorionic twin no miscarriage (n=17); 1.89, triplet no 
miscarriage (n=2)). However these were reduced in women with twin pregnancy affected 
by miscarriage (median of MoM plasma kisspeptin: 0.41, singleton with miscarriage 
(n=50); 0.42, monochorionic twin with miscarriage (n=3); 1.36, dichorionic twin with 
miscarriage (n=7)).   
MoM serum FLT-1 was higher in twin and triplet pregnancies unaffected by miscarriage 
when compared with singleton pregnancies unaffected by miscarriage (median of MoM 
plasma kisspeptin: 1.00, singleton no miscarriage (n=899); 1.35, monochorionic twin no 
miscarriage (n=3); 1.50, dichorionic twin no miscarriage (n=17); 1.87, triplet no 
miscarriage (n=2)). However these were reduced when women had a twin pregnancy 
affected by miscarriage (median of MoM plasma kisspeptin: 0.62, singleton with 
miscarriage (n=50); 0.77, monochorionic twin with miscarriage (n=3); 0.98, dichorionic 
twin with miscarriage (n=7)).  
MoM serum PLGF was higher in dichorionic twin and triplet pregnancies unaffected by 
miscarriage when compared with singleton pregnancies unaffected by miscarriage (median 
of MoM plasma kisspeptin: 1.0, singleton no miscarriage (n=899); 1.00, monochorionic 
twin no miscarriage (n=3); 1.33, dichorionic twin no miscarriage (n=17); 2.01, triplet no 
miscarriage (n=2)). However these were reduced when women had a twin pregnancy 
affected by miscarriage (median of MoM plasma kisspeptin: 0.77, singleton with 
miscarriage (n=50); 0.77, monochorionic twin with miscarriage (n=3); 0.82, dichorionic 
twin with miscarriage (n=7)).  
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Figure 24: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with multiple pregnancy 
and miscarriage.  
Mean ±SEM is shown for S= singleton pregnancy (n=899 no miscarriage and 50 miscarriage), MC= 
monochorionic twin pregnancy (n=3 no miscarriage and 3 miscarriage), DC= dichroionic twin 
pregnancy (n=17 no miscarriage and 7 miscarriage), T=triplet pregnancy (n=2 no miscarriage) 
which did not (no miscarriage) and which did (miscarriage) result in foetal death. No significant 
difference was found when compared by one way ANOVA.  
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Serum Endoglin was only marginally higher in multiple pregnancy (1.1-1.2 in twins or 
triplets unaffected by miscarriage) and only marginally reduced by miscarriage (median 
MOM in singleton miscarriage 0.9) suggesting that serum endoglin is not a good marker for 
identifying women with multiple pregnancy at increased risk of miscarriage.  
This data helps to show that the levels of kisspeptin, BHCG, FLT-1 and PLGF were 
increased with the number of placentae and were reduced when women with twin 
pregnancy were affected by miscarriage of one twin. MOM of plasma kisspeptin appeared 
to be the most useful of the markers evaluated, as it increased from healthy singleton to 
healthy monochorionic to healthy dichorionic to healthy triplet pregnancy and reduced by 
the greatest degree by miscarriage within all of these settings. MOM of plasma kisspeptin 
in twin pregnancies affected by loss of one twin were similar to those seen in healthy 
singleton pregnancy unaffected by miscarriage (median of MoM plasma kisspeptin: 0.23, 
singleton with miscarriage (n=50); 0.82, monochorionic twin with miscarriage (n=3); 1.17, 
dichorionic twin with miscarriage (n=7)). 
However, whilst suggestive, the number of patients with multiple pregnancy was small 
(n=32) making it difficult to draw firm conclusions regarding the utility of these markers 
for the diagnosis of pregnancy complicated by miscarriage. That said, the data set contained 
a larger number of singleton pregnancies, some of whom resulted in miscarriage (n=50) 
whilst the majority resulted in live birth (n=899).  
Therefore I went on to investigate which of the markers performed best in the identifying 
women at increased risk of subsequent miscarriage in asymptomatic singleton pregnancy.   
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with singleton miscarriage:  
 
Fifty of the 949 (5.2%) participants with singleton pregnancy were diagnosed with 
miscarriage after recruitment to the study. The 12
th
 gestational week was the most common 
time for miscarriage to be diagnosed amongst the participants of this study.  
Mean ±SD MOM of plasma PK-1 was 2.1 in women who did not miscarry and 1.83 ±2.0 in 
women who did go on to miscarry suggesting that it was not a good marker for identifying 
women at increased risk of miscarriage.   
Kisspeptin fell the by the greatest proportion in asymptomatic pregnant women who later 
experienced miscarriage when compared with those who went on to have live births. 
Multiples of Median (MoM; gestation-corrected) levels of plasma kisspeptin were 60% 
lower in women who later experienced miscarriage when compared with unaffected 
pregnancies (mean ±SD MoM plasma kisspeptin: 1.04±0.41, singleton no miscarriage, 
0.41±0.41, singleton with miscarriage, P<0.001 vs. singleton no miscarriage) (Figure 25). 
By comparison, MoM levels of serum BhCG were only 36% lower in women who later 
miscarried when compared with pregnancies which did not result in miscarriage (mean 
±SD of MoM plasma kisspeptin: 1.06±0.47, singleton no miscarriage, 0.64±1.1, singleton 
with miscarriage, P<0.001 vs. singleton no miscarriage) (Figure 25).  
Receiver operator characteristic (ROC) curve analysis was performed to determine the 
diagnostic performance of blood markers with respect to miscarriage (Figure 26). Plasma 
kisspeptin had the greatest diagnostic performance with respect to identifying 
asymptomatic women at increased risk of miscarriage (ROC area under curve: 0.86, plasma 
kisspeptin). Furthermore, kisspeptin levels increased to a significantly lesser extent with 
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gestational age, in the cohort of women who experienced miscarriage when compared with 
the cohort of women who had an uncomplicated pregnancy (slope coefficient for increase 
in plasma kisspeptin in pmol/L/week: 305±15, singleton without miscarriage; 94±30, 
singleton with miscarriage; P<0.0001). BHCG was the next best performing marker with an 
area under the ROC curve of 0.83, followed by FLT-1 and PLGF (AUC of ROC curve of 
0.73).  
PK-1 was the worst performing marker evaluaeted for indentifying asymptomatic pregnant 
women at increased risk of miscarriage with an area under the ROC curve of only 0.51 (see 
Figure 26).  
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Figure 25: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with singleton miscarriage:  
Mean ±SEM of Multiples of Median of plasma prokineticin-1 (PK-1), plasma kisspeptin 
(KP), serum BHCG (HCG), serum endoglin (ENG), serum FLT-1 (FLT-1) and placental 
growth factor (PLGF) in healthy singleton pregnancy which did not end in miscarriage (H) 
(n=899) and in women whose pregnancy resulted in miscarriage (M) (n=50).  
Each pair of multiple of medians was compared by unpaired t test.  
** P<0.01, *** P<0.001.  
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Figure 26: ROC of plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, 
Serum Endoglin, Serum FLT-1 and Serum PLGF with singleton miscarriage:  
Receiver Operator Characteristic curves of sensitivity vs 100%-specificity for plasma PK1, 
plasma Kisspeptin, Serum BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF. AUC 
(area under curve) is indicated at the top of each graph.   
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Relationship of plasma kisspeptin with time to diagnosis of miscarriage  
 
Ultrasonography confirmed fetal viability in 13 out of 50 pregnancies following 
participation in the study in patients who subsequently miscarried. Miscarriage occurred a 
mean ±SD of 34.8 ±6.8 days (range 2 - 85) following participation in the study. I therefore 
investigated in more detail the length of time following participation in the study, when 
patients were diagnosed with miscarriage (Figure 27).  
Plasma levels of kisspeptin were significantly lower in patients who miscarried within 8 
days of participation in the study when compared with patients who miscarried further in 
the future. This suggests that plasma kisspeptin levels are even lower in women with 
imminent miscarriage than women who will miscarry further in the future.  
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Figure 27: Changes in plasma levels of plasma Kisspeptin, Serum BHCG and Time to 
miscarriage:  
Mean ±SEM of Multiples of Median of plasma prokineticin 1 (PK1), kisspeptin (KP), 
serum BHCG (HCG), serum endoglin (ENG), serum FLT-1 (FLT-1) and placental growth 
factor (PLGF) in singleton pregnancy resulted in miscarriage within 8 days (<8) (n=16) and 
those resulting in miscarriage after 9 days following recruitment into the study (>9) (n=34). 
Each pair of multiple of median was compared by unpaired t test. * P<0.05.  
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with BMI:  
Obesity is a risk factor for the development of pre-eclampsia, a complication of pregnancy 
occurring during the third trimester which is thought to occur due to abnormal placentation.  
Previous reports have suggested that obese women (BMI >40 kg/m
2
) had lower levels of 
circulating kisspeptin at 16 weeks of pregnancy than lean women ((BMI <25 kg/m
2
) and 
that obese women with pre-eclampsia had lower levels still of kisspeptin than obese women 
(Logie et al. 2012). Therefore I investigated whether the levels of blood markers of 
pregnancy evaluated in this study showed a relationship with BMI (see Figure 28).  
Plasma kisspeptin, serum BHCG, and serum endoglin showed significant falls in levels 
with increasing BMI. Mean MOM of plasma kisspeptin was 1.26 in pregnant women with a 
BMI <20 kg/m
2
 and 0.80 in women with a BMI >35 kg/m
2
. Mean MOM of serum BHCG 
was 1.29 in pregnant women with a BMI <20 kg/m
2
 and 0.85 in women with a BMI >35 
kg/m
2
. Mean MOM of serum endoglin was 1.10 in pregnant women with a BMI <20 kg/m
2
 
and 0.86 in women with a BMI >35 kg/m
2
. 
One might expect that if these plasma markers were merely reflecting placental size that 
women with higher BMI’s would have higher levels than in women with lower BMI’s. 
Therefore it seems feasible that these markers are indeed reflective of placental function 
which is known to be disordered with increased BMI.  
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Figure 28: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with BMI:  
Mean ±SEM of Multiples of Median (MOM) of plasma plasma PK1, plasma Kisspeptin, 
Serum BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF were compared for 
different BMI categories by One way ANOVA with post hoc Dunnet’s multiple 
comparison test versus BMI 15-19.9.  * P<0.05 , ** P<0.01 , *** P<0.001 . 
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with smoking:  
Smoking is known to increase the risk of a number of pregnancy complications, so 
therefore I assessed whether women who were smoking at the time of the antenatal booking 
visit during the first trimester had altered levels of blood markers evaluated when compared 
with non-smoking women in women with singleton pregnancy not resulting in miscarriage.  
Multiple of gestation specific medians of plasma kisspeptin, serum BHCG, and serum 
endoglin were all significantly reduced in pregnant women who smoked when compared 
with women who did not smoke. Placental growth factor was significantly increased in 
non-pregnant women who were smoking at booking when compared with non-smoking 
pregnant women (see Figure 29).  
It is therefore reasonable to speculate that women with increased BMI and women who 
smoked during early pregnancy had lower levels of these blood markers reflecting 
disordered placentation. 
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Figure 29: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with smoking:  
Mean ±SEM of multiples of median of plasma prokineticin 1 (PK1), kisspeptin (KP), 
serum BHCG (HCG), serum endoglin (ENG), serum FLT-1 (FLT-1) and placental growth 
factor (PLGF) in mothers with singleton pregnancy who were smoking at the time of their 
booking antenatal clinic visit (S) (n=34) and in mothers who did not smoke (N) (n=829). 
Each pair of multiple of median was compared by unpaired t test. * P<0.05 , ** P<0.01 , 
*** P<0.001 . 
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with recurrent miscarriage in pregnant 
women whose current singleton pregnancy did not result in miscarriage:  
 
Women with a history of 3 or more consecutive miscarriage are termed as having recurrent 
miscarriage. Recurrent miscarriage occurs in ~1% of fertile couples trying to conceive. 
Chromosomal abnormality is the commonest cause of miscarriage and hence most 
miscarriage is not due to maternal factors. However in recurrent miscarriage, it becomes 
fruitful to screen women for rarer causes of miscarriage including autoimmune or 
thrombotic causes which can then be identified in 50% of women (see table 5 for full list of 
seconday causes of miscarriage).  
Kisspeptin peptide distribution previously found to be reduced in the syncitiotrophoblasts 
of women with recurrent miscarriage (Park et al. 2012). So therefore I investigated whether 
blood levels of pregnancy markers were reduced in women with at least 3 or more 
miscarriages when compared with women a fewer number of previous miscarriage.  
Levels of pregnancy markers were similar in women between 0-2 previous miscarriages 
(see Figure 30). However levels of plasma kisspeptin were significantly reduced in women 
with recurrent miscarriage (at least 3 previous miscarriages) when compared with women 
with a fewer number of miscarriages (mean ±SD MOM of plasma kisspeptin in women 
with <2 previous miscarriages is 1.046 ±0.4067 and in women with 3 or more miscarriages 
is 0.8886 ±0.3822) (see Figure 30). This is consistent with previous data suggesting a 
reduced kisspeptin peptide distribution in syncitiotrophoblasts of women with recurrent 
miscarriage (Park et al. 2012). 
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Figure 30: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with number of previous 
miscarriages in women whose current singleton pregnancy did not result in 
miscarriage:  
Mean ±SEM of Multiples of Median (MOM) of plasma plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF were compared by categories of previous 
miscarriage by One way ANOVA with post hoc Dunnet’s multiple comparison test versus no 
previous miscarriage group. N= 608 for no previous miscarriage, 170 for 1 previous miscarriage, 55 
for 2 previous miscarriage and 31 for at least 3 previous miscarriages.  
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Figure 31: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with history of recurrent 
miscarriages in women whose current singleton pregnancy did not result in 
miscarriage:  
 
Mean ±SEM of Multiples of Median (MOM) of plasma plasma PK1, plasma Kisspeptin, 
Serum BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF were compared by history 
of recurrent miscarriage (3 or more previous miscarriage) (n=31) versus women with up to 
2 previous miscarriages (n=833)  by unpaired t test. * P<0.05 
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with foetal sex:  
 
Kisspeptin is often regarded as a gate-keeper of puberty and the influence of androgens in 
the early neonatal period is thought to be important in influencing with sexual dimorphism 
found in hypothalamic kisspeptin expression (Tena-Sempere 2010).  
It was therefore interesting to see whether maternal kisspeptin levels during pregnancy 
were altered whilst carrying a foetus of either sex. It was interesting to note that both 
kisspeptin and BHCG were significantly higher in women with a female foetus when 
compared with those bearing a male foetus (see Figure 32). However the difference was 
small (mean ±SD MOM of plasma kisspeptin in women carrying a male foetus is 0.99 
±0.39 and in women carrying a female foetus is 1.08 ±0.41). PK-1 was also higher in 
women bearing a female foetus when compared with women bearing a male foetus, 
although this was not statistically significant. None of the remaining markers were 
significantly different in women depending on the sex of the foetus they were carrying (see 
Figure 32).   
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Figure 32: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with foetal sex:  
Multiples of median (MOM) of plasma prokineticin 1 (PK1), kisspeptin (KP), serum 
BHCG (HCG), serum endoglin (ENG), serum FLT-1 (FLT-1) and placental growth factor 
(PLGF) in mothers with singleton pregnancy who gave birth to male babies (M) and in 
mothers who gave birth to female babies (F). Each pair of multiple of medians was 
compared by unpaired t test. * P<0.05, ** P<0.01. 
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with Birth weight:  
Previous reports have suggested that maternal kisspeptin levels were lower in women with 
intra-uterine growth restriction (IUGR) (Armstrong et al. 2009).  
Therefore it was interesting to see whether mothers who gave birth to neonates with low 
body weight had altered levels of pregnancy markers when compared with women who 
gave birth to neonates with normal body weight.  
Low birth weight is often defined as a birth weight less than 2500g (Mcallister et al. 2014). 
As foetal sex independently had an effect on kisspeptin and BHCG levels and foetal sex 
may have an impact on neonatal weight, I analysed the association of these markers with 
birthweight in each foetal sex separately. Plasma kisspeptin was the best performing of the 
pregnancy markers in identifying women who will have babies with low body weight. 
Kisspeptin was significantly lower in women with boys born weighing less than 2500g, 
than in women with boys born weighing 2500-4000g. Furthermore plasma kisspeptin was 
significantly higher still in women with baby boys born weighing more than 4000g. Plasma 
kisspeptin was also lower in women with female neonates weighing less than 2500g, 
although this was not significantly when compared with one way ANOVA with post hoc 
bonferroni correction. Placental growth factor showed a similar pattern of secretion in 
mothers of baby boys, however was not altered in a statistically significant manner.  
This data is consistent with previous reports suggesting that kisspeptin is lower in women 
with intra-uterine growth restriction and provides further evidence that plasma kisspeptin 
may be representative of placental function.  
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Figure 33: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with Birth weight in boys:  
Mean ±SEM of Multiple of Median (MOM) of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF was compared in mothers of male 
neonates by birthweight categories (<2500g, 2500-4000g and >4000g) by one way 
ANOVA with post hoc bonferroni correction. ** P<0.01, *** P<0.001. 
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Figure 34: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with Birth weight in girls. 
Mean ±SEM of Multiple of Median (MOM) of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF was compared in mothers of 
female neonates by birthweight categories (<2500g, 2500-4000g, and >4000g) by one way 
ANOVA with post hoc bonferroni correction.  
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with head circumference:  
 
Another commonly used anthropometric measurement of neonatal size is head 
circumference. Therefore I analysed whether the pregnancy markers evaluated were able to 
identify women bearing neonates with alteration in head circumference. As previously, I 
evaluated the pregnancy markers separately in women bearing male and women bearing 
female foetuses (see Figure 35 and 36).  
Again kisspeptin was the only marker which was significantly altered, being higher in baby 
boys with larger head circumference than those with smaller head circumference.  
None of the other pregnancy markers were significantly altered by category of neonatal 
head circumference.  
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Figure 35: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with head circumference in 
boys.  
Mean ±SEM of Multiple of Median (MOM) of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF was compared in mothers of male 
neonates by categories of head circumference (<33cm, 34-36cm, and >36cm) by one way 
ANOVA with post hoc bonferroni correction. 
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Figure 36: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with head circumference in 
girls.  
Mean ±SEM of Multiple of Median (MOM) of plasma PK1, plasma Kisspeptin, Serum BHCG, 
Serum Endoglin, Serum FLT-1 and Serum PLGF was compared in mothers of female neonates by 
categories of head circumference (<33cm, 34-36cm, and >36cm) by one way ANOVA with post 
hoc bonferroni correction. 
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Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum BHCG, Serum 
Endoglin, Serum FLT-1 and Serum PLGF with prematurity: 
 
Premature delivery is frequently defined as giving birth prior to 37 weeks of gestation.  
Premature delivery is associated with increased neonatal morbidity and could be due to 
abnormal placentation. Therefore I evaluated whether these markers were altered in women 
who gave birth at less than 37 weeks of gestation when compared with women who gave 
birth when they were due (see Figure 37).  
Only PK-1 was statistically significantly altered being lower in women who gave birth 
prematurely than women who gave birth when due.  
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Figure 37: Changes in plasma levels of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF with premature delivery.  
Mean ±SEM of Multiple of Median (MOM) of plasma PK1, plasma Kisspeptin, Serum 
BHCG, Serum Endoglin, Serum FLT-1 and Serum PLGF in women with premature 
delivery (<36 weeks) and in women with delivery which was not premature (>37 weeks). 
Each pair of multiples of median was compared by unpaired t test; * P<0.05.  
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Discussion 
 
A fifth of pregnancies end in miscarriage, and the damaging emotional impact can lead to 
depression and anxiety which may last for several months (Lee et al. 1996). 
PK-1 did not appear to change with gestation, although did appear to be reduced in women 
with premature delivery. Of the markers evaluated, kisspeptin showed the most promise as 
a screening test for identifying asymptomatic women at increased risk of pregnancy 
complications due to abnormal placentation. Women with lower kisspeptin levels corrected 
for gestation had an increased risk of subsequently suffering miscarriage, and women with 
imminent miscarriage had even lower levels of kisspeptin. Kisspeptin had the greatest area 
under a ROC curve for identification of asymptomatic women at increased risk of 
subsequent miscarriage.  
Women who gave birth to boys with low birth weight and small head circumference also 
had lower levels of kisspeptin than in women with babies with normal anthropometric 
parameters. Furthermore, women with risk factors for pregnancy complications due to 
abnormal placentation such as women with increased BMI, women who smoke during 
pregnancy and women with recurrent miscarriage, also had lower levels of plasma 
kisspeptin than gestation-corrected values found in mothers without these risk factors.  
Miscarriage occurs most commonly during early pregnancy, however due to the logistics of 
confirmation of pregnancy and referral for the first antenatal pregnancy visit, most women 
attend their first antenatal screening visit at 8 weeks of gestation or more. At 8 weeks of 
gestation many miscarriages may have already occurred. However miscarriage in early 
pregnancy is predominantly due to foetal chromosomal abnormality and is hence inevitable 
and less amenable to intervention. Miscarriage in later pregnancy is more likely to be 
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associated with treatable causes of miscarriage such as autoimmune or thrombotic 
disorders. It is therefore possible that a safe and mimimally invasive test such as a blood 
kisspeptin level could be used to identify pregnancies at increased risk of pregnancy 
complications such as miscarriage, and this risk stratification could allow for targeted 
obstetric surveillance or intervention in identified women.  
 
In summary, I have shown that plasma kisspeptin measurement in asymptomatic women at 
antenatal booking visit provides a highly predictive marker for identifying asymptomatic 
women at risk of miscarriage and other pregnancy complications.  
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Chapter 4 
 
General Discussion 
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Prokineticin-1 (PK-1) and prokineticin-2 (PK-2) are two closely related cysteine-rich 
peptides which both bind to the prokineticin-1 and prokineticin-2 receptors (PKR-1 and 
PKR-2). The prokineticins were originally named due to their ability to stimulate 
gastrointestinal motility. Since that time, the prokineticins have been found to play a role in 
other biological processes including reproduction and nociception. Prokineticin-2 is known 
to be expressed in regions of the central nervous system involved in food intake. Consistent 
with this, previous work from our own department has shown that administration of 
prokineticin-2 to rodents reduces food intake both in lean and obese rodents.  
However Prokineticin-2 is predominantly expressed within the central nervous system, 
whereas prokineticin-1 is heavily expressed within the gut. I therefore hypothesised that 
prokineticin 1 may be a novel gut hormone. In this thesis, I investigated the physiological 
role of prokineticin-1 in controlling appetite in rodents and also compared its efficacy with 
prokineticin-2. I also measured the changes in plasma levels of prokineticin in humans 
during feeding to establish the potential physiological relevance of prokineticin-1 as an 
anorectic gut hormone.  
Central administration of PK-1 was as effective as equimolar doses of PK-2 at reducing 
food intake. Central PK-1 or PK-2 administration both significantly reduced food intake 
during the first hour following administration down to 22% following 1500 pmol. However 
there were not significant reductions in food intake beyond this time frame suggesting a 
short duration of action.  
If PK-1 were to be used as a therapeutic to combat obesity, it is be important to assess the 
peripheral effects of PK-1 administration. Peripheral IP injection of PK-1 reduced food 
intake by just over half during the first hour following administration. Doses of 20 and 60 
nmol/kg of both PK-1 and PK-2 similarly reduced food intake over the first hour by 
approximately half when compared with saline. Impressively a dose of 540 nmol/kg of 
 162 
either PK-1 or PK-2 reduced food intake by over 90% during the first hour. However the 
effect on food intake had worn off by 4 hrs post administration, suggesting a short duration 
of action.  
I also measured the serum PK-1 levels by a commercial ELISA kit (Peprotech) in mice. 
Serum PK-1 levels were highest at 20 minutes following injection at 40 pg/ml, before 
falling to 10 pg/ml at 60 minutes following administration suggesting a short half life of 
approximately half an hour. This would be consistent with the duration of action of food 
intake during the experiments. Given the short duration of action it would seem reasonable 
that more frequent administration may have more profound effects on body weight over a 
longer period and similar experiments with PK-2 have suggested that tachyphylaxis to the 
prokineticins with repeated administration does not occur.  
PK-1 expression was also reduced in the stomachs of fasted mice. This would be consistent 
with the pattern of expression which would be expected if PK-1 was a physiological gut 
hormone, being low in fasted mice and increasing with food intake to signal satiety to the 
appetite centres in the brain. However if PK-1 was a physiological gut hormone then it 
would be expected that plasma PK-1 levels would be low during fasting and rise following 
food intake signalling satiety. However I was not able to demonstrate a clear effect on 
circulating PK-1 levels in humans following feeding, which may either be due to technical 
issues or due to the existence of other currently unidentified more dominant factors on 
circulating PK-1 levels. Possible technical reasons for not seeing a rise in plasma PK-1 
levels may be due to difficulties in measuring circulating PK-1 with the antibodies used in 
current commercially available ELISA kits, as many participants had levels which were 
towards the lower end of the sensitivity of the assay. Another possibility is that other 
unidentified factors may influence plasma PK-1 levels to a greater degree than those seen 
following feeding. Reliability of the assay may have been compromised by interfering 
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factors, binding proteins or non-specificity of the antibody, making it difficult to draw firm 
conclusions regarding circulating levels of PK-1 with feeding. We are in the process of 
developing our own in-house prokineticin assay in order to be able to more accurately 
characterise the circulating levels of PK-1 with feeding and during pregnancy.  
In summary, I have demonstrated that both central and peripheral administration of PK-1 
potently reduces food intake and that experession of PK-1 levels in the stomachs of mice 
change in manner consistent with that of a physiological gut hormone. PK-1 therefore 
represents a novel target for the development of anti-obesity therapies. The efficacy of 
some anorectic hormones in obesity is limited by resistance in obesity models, such as seen 
with leptin. However prokineticin-2 has been shown to be effective in diet induced obese 
mice (Gardiner et al. 2010). Furthermore, some anti-obesity therapies can be susceptible to 
tachyphylaxis with repeated administration such that seen with melanocortin agonists 
(Gardiner et al. 2010). However the prokineticins do not appear to be susceptible to 
tachyphylaxis with repeated dosing (Gardiner et al. 2010). The discovery of novel gut 
hormones is important, in that there is likely to be redundancy in the system with multiple 
gut hormones being involved in controlling appetite. It is likely that multiple agents with a 
small individual effect will need to be used in combination at small doses in order to 
minimise side effects whilst having additive effects on reducing food intake. Prokineticin-1 
may therefore represent an important target for the development of anti-obesity therapies.  
 
Prokineticin-1 is also a potent angiogenic mitogen on endocrine vascular epithelium and 
hence it is also known as ‘Endocrine Gland-Vascular Endothelial Factor’. Placental 
angiogenesis plays an important role in placental function and risk of pregnancy 
complications such as miscarriage. I therefore hypothesised that prokineticin-1 is a 
biomarker of pregnancy complications in humans. In this thesis, I have measured 
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circulating levels of prokineticin-1 found in pregnancy and correlated these with the 
occurrence of pregnancy complications. I have also compared the utility of prokineticin 1 
with other potential novel markers of pregnancy complications.  
Circulating PK-1 levels did not appear to be the best performing marker for identifying 
complications associated with pregnancy. PK-1 did not change with gestation, although did 
appear to be reduced in women with premature delivery. Of the markers evaluated, plasma 
kisspeptin showed the most promise as a screening test for identifying asymptomatic 
women at increased risk of pregnancy complications due to abnormal placentation. Women 
with lower kisspeptin levels corrected for gestation had an increased risk of subsequently 
suffering miscarriage, and women with imminent miscarriage had even lower levels of 
kisspeptin. Kisspeptin also had the greatest area under a ROC curve for identification of 
asymptomatic women at increased risk of subsequent miscarriage.  
Women who gave birth to boys with low birth weight and small head circumference also 
had lower levels of kisspeptin than in women with babies with normal anthropometric 
parameters. Furthermore, women with risk factors for pregnancy complications due to 
abnormal placentation such as women with increased BMI, women who smoke during 
pregnancy and women with recurrent miscarriage, also had lower levels of plasma 
kisspeptin than gestation-corrected values found in mothers without these risk factors.  
Miscarriage occurs most commonly during early pregnancy, however due to the logistics of 
confirmation of pregnancy and referral for the first antenatal pregnancy visit, most women 
attend their first antenatal screening visit at 8 weeks of gestation or more. At 8 weeks of 
gestation many miscarriages may have already occurred. However miscarriage in early 
pregnancy is predominantly due to foetal chromosomal abnormality and is hence inevitable 
and less amenable to intervention. Miscarriage in later pregnancy is more likely to be 
associated with treatable causes of miscarriage such as autoimmune or thrombotic 
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disorders. It is therefore possible that a safe and mimimally invasive test such as a blood 
kisspeptin level could be used to identify pregnancies at increased risk of pregnancy 
complications such as miscarriage, and this risk stratification could allow for targeted 
obstetric surveillance or intervention in identified women.  
In summary, I have shown that plasma kisspeptin measurement in asymptomatic women at 
antenatal booking visit provides a highly predictive marker for identifying asymptomatic 
women at risk of miscarriage and other pregnancy complications.  
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Appendix 1:  Solutions 
 
Bovine serum albumin (BSA) solution (2mg/ml):  Dissolve 2g of BSA in 1l of 0.01M 
PBS. 
 
0.5M ethylenediaminetetra-acetic acid (EDTA): In 800ml autoclaved water dissolve 
186.1g C10H14H2O8Na2.2H2O and adjust to pH 8.0 with 1M NaOH. Make up to 1L with 
water. 
 
Phosphate buffer (RIA buffer): 48g of Na2HPO4.2H2O, 4.13g KH2PO4, 18.61g 
C10H14H2O8Na2.2H2O, 2.5g NaN3 were dissolved in 5L of GDW, which had been boiled 
and allowed to cool, the pH was measured to confirm it was 7.4 ± 0.1 and the buffer was 
stored at 4
o
C. 
  
0.01M phosphate buffered saline (PBS):  Carry out a 1:100 dilution of 1M PBS as 
prepared above. 
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Appendix 2:  Amino Acid Codes 
Amino Acids Codes 
 Three letter Single letter 
Glycine Gly G 
Proline Pro P 
Alanine Ala A 
Valine Val V 
Leucine Leu L 
Isoleucine Ile I 
Methionine Met M 
Cysteine Cys C 
Phenylalanine Phe F 
Tyrosine Tyr Y 
Tryptophan Trp W 
Histidine His H 
Lysine Lys K 
Arginine Arg R 
Glutamine Gln Q 
Asparagine Asn N 
Glutamic Acid Glu E 
Aspartic Acid Asp D 
Serine Ser S 
Threonine Thr T 
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Appendix 3:  List of Suppliers 
Abnova, Taiwan 
Abbott Animal Health, Kent, UK 
Adam Equipment, Milton Keynes, UK. 
Advanced Biotechnology Centre, Imperial College London, UK 
Ambion, Warrington, UK) 
Amersham International plc, Little Chalfont, Buckinghamshire, UK. 
Associated Dental Products Ltd, Kemdent Works, Purton, Swindon, UK 
ATCC, Middlesex, UK 
Bachem St. Helens, UK 
Bayer UK, Bury St. Edmonds, UK 
BOC Gases, Guildford, Surrey, UK 
Bright Instruments, Huntingdon, UK 
Charles River, Margate, UK. 
Clark Electromedial Instruments, Pangbourne, Reading, UK 
Columbus Instruments, Columbus, Ohio, USA 
CrystalChem, Illinois, USA 
Dako UK Ltd., Cambridgeshire, UK 
Durect Corporation, Cupertino, CA, USA 
Fisher Scientific, Leicestershire, UK 
Gibco BRL (Life Technologies Ltd.), Paisley, Renfrewshire, UK. 
GraphPad, La Jolla, CA, USA 
Harlan, Bicester, Oxon, UK 
Harvard Apparatus, Massachusetts, USA 
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Helena Biosciences, Sunderland, UK 
Invitrogen, Paisley, UK 
Johnson and Johnson, Livingston, UK 
Life Sciences Technology, Eggenstein, Germany 
Merck Chemicals Ltd., Nottingham, UK 
Millipore, Watford, Herts, UK 
New England Bioloabs, Hitchin, Herts, UK 
Novagen, Nottingham, UK 
Parke-Davis, Pontypool, Gwent, UK. 
Peninsula Laboratories, St Helen’s, UK 
PeproTech Ltd., London, UK 
Peptide Institute, Kyoto, Japan. 
Perkin Elmer, Massachusetts, USA 
Pharmacia Biotechnology Ltd., St. Albans, Hertsfordshire, UK. 
Plastics One Inc, Roanoke, VA, USA. 
Promega, Southampton, UK 
Qiagen, Hilden, Germany. 
Reno, NV, USA 
Research Diets Inc, New Brunswick, NJ, USA 
Roanoke, VA, USA 
Santa Cruz Biotechnology Inc., California, USA 
Schering-Plough Corporation, Welwyn Garden City, Herts, UK 
SDS UK Ltd, Witham, Essex, UK. 
Seton Healthcare, Oldham, Lancs, UK 
Shandon Southern Products, Runcorn, Cheshire, UK 
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Sigma-Aldrich Company Ltd., Poole, Dorset, UK. 
StataCorp, College Station, Texas, USA 
Systat Ltd., Evanston, Illinois, USA. 
VetTech Solutions, Cheshire, UK 
VWR, Poole, UK 
 
 
 
 
 
 
 
 
 
 
 
 
 
